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 Coronin 1C is overexpressed in multiple tumors, leading to the widely held view that 
this gene drives tumor progression, but this hypothesis has not been rigorously tested in 
melanoma. Here, we combined a conditional knockout of Coronin 1C with a genetically 
engineered mouse model of PTEN/BRAF-driven melanoma. Loss of Coronin 1C in this 
model increases both primary tumor growth rates and distant metastases. Coronin 1C-null 
cells isolated from this model are more invasive in vitro and produce more metastatic lesions 
in orthotopic transplants than Coronin 1C-reexpressing cells due to the shedding of 
extracellular vesicles (EVs) containing MT1-MMP. Interestingly, these vesicles contain 
melanosome markers suggesting a melanoma-specific mechanism of EV release, regulated 
by Coronin 1C, that contributes to the high rates of metastasis in melanoma.
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CHAPTER 1: INTRODUCTION 
Actin and Type 1 Coronins 
The actin cytoskeleton has many functions in cell biology including motility, polarity, 
trafficking, contractility, and maintenance of cell shape. Monomeric actin (G-actin) 
polymerizes to create strands of filamentous actin (F-actin)1  in a tightly regulated fashion 
influenced by a variety of different molecular players that control the assembly and 
disassembly of filaments, the structure of the larger actin network, and its location within the 
cell. F-actin and its binding partners are capable of forming numerous structures including 
the cytokinetic ring, bundled actin responsible for structures such as filopodia, tracks for 
vesicles and organelles to travel along, and fan-like networks of branched F-actin called 
lamellipodia which provide the protrusive force necessary to drive the membrane forward 
during migration.  
At the front of the lamellipodia, F-actin elongates at the barbed (or +) end of 
filaments and is decorated with a high concentration of ATP-bound F-actin. Newly 
synthesized ATP-F-actin hydrolyzes to ADP-Pi-F-actin quickly as new monomers are added 
onto the barbed end. While this process of nucleotide exchange happens almost instantly as 
monomeric G-actin is incorporated into the filament, dissociation of the additional Pi is a 
slower process2. This creates a polarity within the actin filament where the barbed end is 
composed primarily of ATP-F-actin and ADP-Pi-F-actin while the pointed end is composed 
mostly of ADP-actin with some ADP-Pi-F-actin and very little ATP-F-actin which causes a 
slight conformational change in the filament. This composition of the pointed end encourages 
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cleavage by cofilin as the filament elongates3, and the G-actin monomers are released from 
these older sections at the pointed (or -) end of the filament exchange ADP for ATP via 
Profilin. Once ATP-bound, monomers are able to be reincorporated into F-actin on the 
barbed end of the filament at the front of the lamellipodia in a dynamic process known as 
actin filament treadmilling, creating a membrane protrusion4. 
Coronins are a highly conserved family of proteins first identified by their crown-like 
structure localized on the dorsal surface of Dictyostelium discoideum5. There are seven 
mammalian coronins, characterized by actin binding through their WD40 repeat and β-
propeller domain6, divided into three groups based on sequence similarity. Coronin 1C is part 
of the type 1 coronin group, along with Coronin 1A and Coronin 1B, that is best known for 
its activity in regulating F-actin at the lamellipodia7–9. Characteristic localization to the edge 
of lamellipodia is displayed in Figure 1.1.   
Figure 1.1 Coronin 1C 
localization to the leading 
edge of lamellipodia. 
PCB885 melanoma cells 
null for Coronin 1C were 
rescued with Coronin 1C-
GFP at physiological levels 
and captured using Zeiss 
800 confocal microscope, 
40x. Scale bar = 25 µM. 
Strong signal can be seen 
banding around the leading 
edge as well as at puncta  






 At the lamellipodia, and at other sites of branched actin in the cell, coronins interact 
with a variety of actin binding proteins, as well as with F-actin itself, to influence the 
dynamics of branching, assembly, and disassembly. Much of this activity centers around the 
key actin nucleator Arp2/310,11 which is a seven-protein complex that binds to existing F-
actin and nucleates new daughter filament branches at a characteristic 70⁰ angle12. 
Historically, it has been shown that coronins are capable of binding directly to the Arp2/3 
complex and both inhibit its activity at areas of low density filaments and exacerbate its 
activity where filaments are abundant to promote additional branching in vitro10,13–15.  
 Recent work out of Bruce Goode’s lab has shown that coronin regulates actin 
dynamics by enhancing the binding of Cofilin, a highly conserved actin depolymerizing 
protein, to branched actin at the leading edge of cells9,16. Goode’s group identified a 
conformational change in the actin filaments upon binding of coronin through the well-
conserved β-propeller domain14 that reduces the flexibility of the nucleotide-binding cleft, 
creating a more open confirmation that primes F-actin for cofilin binding16 and actin 
turnover. Decades of research have shown that Cofilin preferentially binds to ADP-F-actin 
while coronin binds to ATP/ADP-Pi actin so the mechanism by which these two synergize to 
promote severing and depolymerization remains to be determined.  
 These data suggest a model for coronin where the relative localization of coronin 
dictates the subsequent effect on Arp2/3-mediated branching and Cofilin-mediated 
disassembly, therefore enabling coronins to spatially control actin dynamics within the cell. 
This is strongly dependent upon the ATP/ADP state of the actin filaments as well as the 
concentration of filaments within the space. This dichotomy is ultimately thought to aid in 
the assembly and branching of F-actin at the front of the lamellipodia while encouraging 
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branch disassembly and recycling at the rear, creating a dynamic and forward-moving 
lamellipodium required for cell migration. 
Coronin 1C  
Coronin 1C is the least-well described of the type 1 coronins. Much of the work done 
describing canonical coronin function described above was done exclusively with coronin 
1A, coronin 1B or the yeast homolog from which they arose. Coronin 1C has been shown to 
co-immunoprecipitate with Arp2/3 and localize well to the leading edge of migration 
cells17,18, and some very basic work has been done to confirm that coronin 1C is involved in 
cell migration, cell protrusion, and proliferation19 though the mechanistic work describing 
how coronin 1C regulates these activities is largely incomplete7.  
Coronin 1A is mainly expressed in hematopoietic cells and neuronal tissue, while 
Coronin 1B and Coronin 1C are more ubiquitously expressed throughout the body7. While 
Coronin 1B levels remain relatively constant with the exception of its upregulation following 
spinal cord injury20, Coronin 1C expression levels fluctuate significantly, especially in the 
context of disease21. These expression changes are regulated at the transcriptional level 
through c-Myc/Max and Slug/Snail/E47 all of which do not seem to regulate the transcription 
of other coronin proteins22. 
Coronin 1C is also a unique target for post-transcriptional modifications compared to 
its other type 1 family members. The relative abundance of Coronin 1C is regulated by a 
variety of miRNAs that target the mRNA prior to translation23–25 and the activity of the 
protein may be further regulated through multiple sites of phosphorylation. Coronin 1A and 
Coronin 1B are regulated by the kinase PKC at serine 2 and this process is stimulated by 
addition of PMA in vivo11,26. There is evidence that Coronin 1C can be phosphorylated based 
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on information in proteomic databases and has been shown to be phosphorylated at serine 
463 by protein kinase CK227. There is also evidence that Coronin 1C is regulated by the 
protein phosphatase PTP1B, suggesting that there is at least one tyrosine phosphorylation site 
active on Coronin 1C, though the location has not been determined28. 
Expression patterns and post translational modifications are not the only things that 
set Coronin 1C apart from its family members. It was widely accepted that all of the type 1 
coronins share an actin binding site in the β-propeller domain and while this is indeed true, 
our lab identified another actin binding site in Coronin 1C’s unique region that is not present 
in the other type 1 coronin proteins29. Both of these actin binding sites were required for 
Coronin 1C localization to the leading edge, suggesting that Coronin 1C’s interaction with F-
actin is required for its function in regulating lamellipodia dynamics.  
In addition to its role in branched actin regulation at the leading edge, there is a 
growing body of evidence that Coronin 1C plays a unique role in multiple stages of the 
vesicular trafficking pathway. In pancreatic β-cells Coronin 1C activity is required for 
efficient endocytosis of the plasma membrane30 (Kimura et al 2010 biochemical and 
biophysical research). Interestingly, this process is independent of Arp2/3 binding and is 
instead regulated by the direct binding of Coronin 1C with Rab27a31. Rabs are a large family 
of sixty-seven mammalian proteins which localize to various organelles and to the exterior of 
vesicles to aid in sorting and translocation within the endolysosomal pathway32. Rab27a is 
well known for regulation of various exocytic events, particularly for its importance in 
melanosome transport in melanocytes.  
Coronin 1C has also been implicated further along the endolysosomal pathway in ER-
associated endosome fission events. Recruitment of Coronin 1C to endosomal buds and 
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association with TMCC1 is necessary for fission to occur33. After the budding event, Coronin 
1C remains on the endosome as it is trafficked on, though its function at this point is not 
understood. While there is not yet evidence of Coronin 1C’s involvement in exocytosis 
events, work from Alissa Weaver’s lab has identified Coronin 1B to be crucial for 
stabilization of the branched actin network at the plasma membrane, necessary for the release 
of exosomes34. 
Coronin 1C in Cancer 
Coronin 1C is the only type 1 coronin that is consistently implicated in cancer 
progression. There are a wide variety of studies demonstrating the correlation between its 
expression and the progression of multiple cancers including gastric cancer35, diffuse 
gliomas36, hepatocellular carcinoma37, and breast cancer38,39. There are no published studies 
solely examining the expression of Coronin 1C in melanoma, though there is a panel 
showing increased Coronin 1C expression upon worsening prognosis in human biopsies in a 
2008 review by David Roadcap21.  While no work had been published pursuing the further 
understanding of those observations in melanoma, there has been some work describing 
Coronin 1C’s functional role in other cancer types. Nearly all of this research has been done 
in in vitro cell systems examining the effects of Coronin 1C knockout or overexpression on 
tumor cell migration and proliferation.  
Many functional studies have perturbed Coronin 1C expression and function in 
cancer cells through use of cancer-associated microRNA (miR) including miR-123, miR-
133a24, and miR-20625. Reduced expression of Coronin 1C using this method resulted in 
decreased tumor cell proliferation rates, and inhibition of invasion through Boyden Chambers 
was observed. In addition, the efficacy of miR-1 was examined in vivo through orthotopic 
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injection of gastric cancer and breast cancer cells either treated with miR-1 or scrambled 
miRNA into nude mice23. The tumor volume of the miR-1 treated cells was diminished 
through the five weeks following injection when compared to the control tumors. These 
studies may provide functional data of specific miRNAs on cancer cell proliferation and 
migration, but caution should be taken when gleaning insight of Coronin 1C function. A 
single endogenous miRNA is capable of influencing the expression and activity of hundreds 
of different mRNAs40, so a more targeted approach should be used to determine the exact 
mechanism driving these observations.  
Other studies have used shRNA and siRNA to selectively knock down Coronin 1C 
expression in glioblastoma and breast cancer cell lines. Inhibition of Coronin 1C with these 
methods also resulted in decreased cell proliferation and transwell invasion41, and an 
organotypic culture of glioblastoma cells with knockdown of Coronin 1C resulted in 
decreased invasion into ex vivo entorhinal cortex42. Conversely, overexpression of Coronin 
1C led to a more invasive phenotype in this model. 
While much of this work is intriguing and suggests an advantageous role of Coronin 
1C overexpression in cancer progression, more translational research should be done to 
understand how Coronin 1C functions in a native environment. Arguably the best cancer 
model for loss of Coronin 1C to date (aside from that described in detail in chapter 3) is 
described in a recent paper out of the Clemen lab at the University of Cologne, Germany, 
where a homozygous knock-out of Coronin 1C was attained to study its role in 
glioblastoma43. In this model, the authors were unable to find any clear or significant 
difference between glioblastoma proliferation rates or overall survival in the Coronin 1C 
knockouts compared to the control strain. The authors instead moved into U373 glioblastoma 
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cells and used overexpression and shRNA-mediated knockdown of Coronin 1C to study its 
function. Given this development, it is clear that more work needs to be done in order to 
understand the discrepancies between the apparent tumorigenic activity of Coronin 1C in 
vitro compared to its lack of impact in properly modeled in vivo systems. Significant 
attention to translational model systems and methods of study will be crucial for this 
undertaking. 
Melanoma 
Melanoma is described as a malignant tumor arising from melanocytes, which are the 
cells in skin that produce the pigment melanin. The rate of melanoma diagnoses is increasing 
faster than any other cancer type44 and is now the fifth most common cancer diagnosis with 
an estimated one hundred thousand new cases in 2020 in the United States alone, with most 
occurring in white men aged 55-74. While overall survival rates are quite good for most 
melanoma patients, prognosis worsens significantly upon metastasis of the primary tumor, 
from 99% survival to just 27.3% survival, beginning in stage III and continuing into stage 
IV45. At these later stages, the tumor is not able to be fully resected through surgery and 
alternative treatments such as chemotherapy, radiation, targeted therapies, and 
immunotherapies are deployed to combat the disease46.  
The most common genetic drivers of melanoma are activating mutations in BRAF, 
NF1, and NRAS that typically arise from exposure to DNA-damaging UV light47–49,49. 
Chapters 2 and 3 demonstrate the use of genetically engineered mouse (GEM) models to 
study BRAF-mutant melanoma which accounts for about 50% of melanoma cases50. The 
most common activating mutation in BRAF is a substitution of valine for glutamic acid at 
amino acid 600 (V600E), which was employed as a driver mutation in these mouse models. 
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Upon acquisition of one or more driver mutations, collections of proliferative melanocytes 
(nevi) form (Figure 1.2). These nevi may be harmless and regress to a normal state, but 
accumulation of more mutations in genes such as PTEN, TERT, or CDKN2A48,51 will lead to 
radial growth along the lower epidermis and/or vertical growth deeper into the tissue, across 
the natural barrier of the basement membrane (BM). Once past the BM, cells may break 
away from the primary tumor and generate distant metastases, commonly through 
intravasation into the blood stream52,53. The most frequent sites for melanoma metastases to 
take root include the liver, lung, and brain resulting in devastating decline in survival 
projections54. 
 
Figure 1.2. Melanoma progression model. 
A normal melanocyte in the epidermis progresses to late stage metastatic melanoma. 
Melanocytes divide within the epidermis to create nevi. These nevi may stay benign or 
progress to the radial growth phase, where proliferation and spread occurs laterally, and/or 
progress to the vertical growth phase where melanoma cells penetrate the basement 
membrane and invade the dermis. Metastatic melanoma is represented by intravasation into a 
dermal blood vessel. Adapted from the literature55,56. 
 
There have been multiple successful clinical trials and treatment options deployed for 
targeted therapy against BRAF and its upstream effector MEK (both alone and in 
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combination) for the treatment of BRAF-mutant melanoma57–61 and while many show 
promising decline in tumor volume early in treatment, patients often suffer from debilitating 
drug resistance after a period of about twelve months62. Melanoma’s unique propensity for 
metastasis combined with largely ineffective therapies presents a dire need to better 
understand the mechanisms driving progression and spread to help improve patient 
outcomes.  
 In order to better understand molecular and mechanistic drivers of melanoma, one 
must first have a firm grasp of the melanocyte cells from which this cancer arises. 
Melanocytes comprise a small number of cells present in the base of the epidermis which are 
responsible for producing the pigment melanin and feeding packages of mature melanin to 
keratinocytes. A single melanocyte is capable of delivering melanin to up to 40 neighboring 
keratinocytes through long dendritic projections, giving these cells a spindly phenotype63.  
Being a specialized producer of melanin, melanocytes have a dedicated and highly 
regulated process of biogenesis, maturation, transport, and secretion. Packages of melanin, 
called melanosomes, are closely related to lysosomes and undergo four maturation stages 
during biogenesis. Progression of melanin to its mature and pigmented form is driven by 
Tyrosinase and Tyrosinase related proteins 1 and 2 (Trp1 and Trp2)64,65 in stages III and IV 
of maturation66. Throughout biogenesis, Rab27a interacts with Slac2-a/Melanophyilin  and 
Myosin Va to aid in transport of melanosomes to the cell exterior along tracks of actin 
filaments67,68, and mutations in any of these proteins lead to pigmentation defects due to the 
inability to transfer melanin to the cell surface and ultimately to neighboring keratinocytes69–
71.   
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While the process of maturation and transport of melanosomes within melanocytes is 
relatively well understood, the mechanism of transfer to neighboring keratinocytes is still 
debated63,72. There are four proposed mechanisms of transfer that all include movement of 
mature melanosomes from the cytoplasm of melanocyte protrusions to the cytoplasm of 
neighboring keratinocytes (Figure 1.3). The first mechanism, called cytophagocytosis, 
involves passage of multiple melanosomes to the tips of melanocyte projections where the 
entire tip, including some of the melanocyte PM, is internalized by a keratinocyte creating a 
double membrane vesicle73. The second proposed method of transfer involves the fusion of 
the melanocyte PM with the keratinocyte PM to generate a tubule in which melanosomes can 
be transferred before the connection is broken off and the PMs return to their normal state74. 
 
Figure 1.3 Proposed mechanisms of melanosome transfer. 
Melanosomes are transported from melanocytes to keratinocytes across long, fingerlike 
projections. The four proposed mechanisms of transfer at these projections are 
cytophagocytosis, fusion, shedding phagocytosis, and exocytosis. These mechanisms are 
illustrated with melanosomes in brown, melanocytes in blue, and keratinocytes in green. 




There is little evidence to support the first two models of melanosome transfer, 
though much more work has been done to visualize the latter two. The model of vesicle 
transfer, or the shedding-phagocytosis model, has been widely characterized and involves the 
shedding of membrane-bound microvesicles that bud directly from the PM containing 
clusters of melanosomes that are released from tips of the melanocyte into the extracellular 
space. These vesicles are then phagocytized by a neighboring keratinocyte creating a double 
membrane vesicle within the keratinocyte cytoplasm63,72,76,77 similar to those described in the 
first method. The last proposed method involves exocytosis of individual melanosomes into 
the extracellular space, similar to multivesicular body (MVB) fusion with the PM, which are 
then endocytosed by the keratinocytes one-by-one78,79. 
 While many may not consider these day-to-day activities of melanocytes important 
for the biology of cancer, a largely underexplored area of research is the idea of lineage 
dependency, where cancer cells benefit from intrinsic characteristics of the cell type from 
which it originated, or from regression of a differentiated state back to a precursor state80. 
Melanocyte biology holds a host of potentially useful traits for cancer progression. 
Particularly, the endolysosomal trafficking pathway which has been closely tied to 
melanosome biogenesis and transfer has been identified as upregulated in malignant 
melanoma, mainly through aberrant activity of Rab781. The specific wiring of this pathway in 
melanocytes is required for the maintenance of melanoma proclivity while seemingly 
dispensable for the success of other cancer types81. This rogue trafficking pattern could have 
wide-reaching impact on melanoma progression considering the vital role for the 
endolysosomal pathway in protein recycling, degradation, and secretion.  
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Melanoma cells could benefit from not only precursor dermal melanocyte function, 
but also from lineage-specific traits of the very plastic and highly migratory neural crest cells 
(NCCs) from which they originate. During development NCCs migrate dorso-laterally from 
the neural tube to what will later become the dermis before differentiating into 
melanocytes82. This process is highly regulated through the master regulator genes MITF and 
slug, a member of the snail family, which drive migration and cellular differentiation upon 
arrival and then become silent as the cells settle into their role as melanocytes83. 
Interestingly, slug is also a known regulator of Coronin 1C transcription22. Inappropriate 
reactivation of both MITF and slug have been observed in aggressive melanoma84,85 and are 
thought to aid in epithelial to mesenchymal transition (EMT) and invasion, driving metastasis 
and disease progression86.  These lineage-specific functions may help to explain the extreme 
metastatic potential for this cancer type, which accounts for 80% of deaths from all skin 
cancers while only encompassing 5% of skin cancer diagnoses60. 
Invasion and Matrix Metalloproteinases   
While cells may be able to squeeze through a disperse 3D extracellular matrix (ECM) 
network, both healthy and cancerous cells often find themselves confined by their 
surroundings. In addition to the hurdle of breaking away from the primary tumor and 
migrating through the ECM, one of the most challenging steps for invasive  melanoma cells 
to overcome is passage through the dense cutaneous BM that separates the epidermis from 
the papillary dermis and macro-vasculature87. The BM consists of a dense network of 
glycoproteins and proteoglycans including an abundance of collagen proteins and isotypes, 
laminin, heparan sulfate, and fibronectin that serves as barrier separating cell populations on 
either side and also physically anchors the epidermis88. Once through the BM and into the 
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dermis, the invading cells will face a variety of other obstacles broadly including 
intravasation, extravasation, and establishment of the secondary tumor site.  
Matrix metalloproteinases (MMPs) are a large family of human proteins that are 
capable of cleaving a wide variety of these ECM components. In cancer cells, this cleavage is 
crucial for movement through dense networks, invasion through the BM, and establishment 
of secondary tumor sites89–91. Most MMPs are soluble, but some are trans-membrane proteins 
(labeled “MT” for “membrane-type”). Soluble MMPs are typically released into the 
extracellular space in exosomes which disperse locally before the membrane degrades and 
the MMPs can begin to cleave the surrounding matrix to drive directional movement toward 
the less-dense network92. MT-MMPs are typically presented at the PM near the front of an 
invading cell, where the catalytic domain is presented extracellularly and cleaves the ECM 
directly up against the membrane.  
The most commonly described structure responsible for localized targeting of MMP 
activity to promote cancer cell invasion is the invadopodium. Invadopodia are finger-like 
projections, anchored by integrin engagement and focal adhesions, that protrude from the PM 
of invading cancer cells driven by the polymerization and bunding of actin filaments through 
the activity of Tks5, N-WASP, Arp2/3, cofilin, and cortactin93–97. At invadopodia, soluble 
MMP2 and MMP9 are secreted in exosomes to promote degradation of collagen (IV-VII, X, 
XIV), elastin, fibronectin, and fibrillin. In addition, MT1-MMP is presented on the PM at the 
tip of these structures and cleaves collagen (I-III), fibronectin, laminin, aggrecan, and 
tenascin91,94 adjacent to the cell membrane.  
Invadopodia have been very well described in vitro and their importance in systemic 
invasion, intravasation, extravasation, and establishment of the secondary tumor site has been 
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extrapolated from these studies97. However, there is still some question as to whether these 
structures are important for, or even present in, in vivo metastasis. It is clear that many of the 
structural proteins associated with invadopodia are essential for invasion to occur such as 
Cortactin98,99, N-WASP100, and Tks5101,102 but the exact mechanism by which these proteins 
impact tumor cell invasion in vivo is not well described. These studies came to their 
conclusions through counting metastasis events following knockdown or knockout of their 
protein of interest in cancer cells paired with injection into mice, and while this method does 
provide insight to the importance of these proteins in invasion, there was no evidence that the 
cells created invadopodia in vivo. 
MT1-MMP (also known as MMP-14) is a membrane-type matrix metalloproteinase 
that is described as one of the most important MMPs for cancer invasion103–106. Its expression 
and activity has been implicated in many cancer types including melanoma104. MT1-MMP is 
translated to a latent ~72 kilodalton (kd) protein before being cleaved to its ~60kd 
catalytically active form during transit to the PM107. As stated previously, MT1-MMP is 
often associated with invadopodia-mediated invasion and is capable of cleaving a wide 
variety of ECM components, aiding in invasion of many cancer types. MT1-MMP is also 
responsible for the cleavage and activation of MMP2 although invasion is still prominent in 
cells where this function is silenced108. 
MT1-MMP’s location is tightly regulated, largely through clatherin-mediated 
endocytosis via a dileucine motif on its cytoplasmic tail in conjunction with EndoA2 and 
dynamin-263. Internalized vesicles are trafficked through the endolysosomal pathway along 
microtubules, dependent upon Rab8, Rab7, and VAMP-7 for relocation to the leading edge 
or invadopodia103,106,109,110. Endosomal actin networks around the vesicle formed through 
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WASH and Arp2/3-mediated F-actin branching are crucial for trafficking to the cell 
surface111 where the recycling endosome fuses with the PM and MT1-MMP is again able to 
cleave ECM adjacent to the cell membrane. While less well described, MT1-MMP has also 
been shown to be secreted out of the cell in exosomes with the catalytic domain presented 
outward112. In this instance, the recycling endosomes containing MT1-MMP undergo 
invagination to create smaller vesicles within the endosome, forming MVBs. These MVBs 
then fuse with the PM to secrete the extracellular vesicle (EV) cargo containing catalytically 
active MT1-MMP on their surface.  
In addition to its catalytic function, MT1-MMP has also been implicated in an array 
of housekeeping and pro-tumorigenic functions including angiogenesis113–115, 
proliferation110,116,117, and adipogenesis90 through a variety of non-catalytic binding partners 
including integrins, chemokines, and antimicrobial peptides.  MT1-MMP promotes VEGF 
expression through phosphorylation and activation of Src kinase, promoting more blood flow 
for primary tumor growth and potentially establishment of a metastatic niche118. MT1-MMP 
also plays a role in transcriptional regulation of the targets Notch1, PI3Kδ and SPRY4119,120. 
Repression of SPRY4 is a particularly interesting function due to its role in neural crest cell 
formation, migration, and differentiation121,122 which could have a lineage-specific effect in 
melanoma compared to other types of cancers. How MT1-MMP is regulating transcription is 
not well understood, but is thought to either traffic to the nucleus to act as a direct 
transcriptional regulator119 or act through other players such as Rac1120. 
Animal Models of Cancer 
 The study of cellular processes and molecular mechanisms through in vitro cell 
biology, molecular biology, and biochemistry are paramount for understanding the role of 
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specific proteins and cell structures in both healthy cells and in a disease state. However, 
cells grown in standard 2D tissue culture, where countless cancer studies have been 
conducted, may behave completely differently from how they would in their native 
environment. For example, research studying the roles of NEDD9, Vinculin, Zyxin, and 
p130Cas in cell migration yielded opposite responses to loss of function or expression just by 
changing from a 2D to 3D migration system123–125. The change from 2D to in vivo is a much 
more drastic jump, suggesting a potential for serious deviation of observed phenotypes. 
Choosing a proper model system for the study of protein function in the context of cancer 
research is especially important because the ultimate goal is to identify a protein’s impact on 
disease progression. Pairing in vivo phenotypes with in vitro mechanistic studies provides a 
more wholistic understanding of protein function that just one system alone cannot provide.  
 Some of the earliest mouse models of cancer involved the transplantation of cultured 
human cancer cell lines, called cancer cell line-derived xenografts (CDX). Patient-derived 
xenographs (PDX) are very similar in concept but introduce the advantage of personalized 
medicine by the opportunity to test individualized treatment combinations on the patient’s 
own cancer cells in vivo. The major hurdle to cross for getting tumors to take in these models 
was overcoming the mouse immune response that clears foreign cells from the body. To 
work around this, CDX and PDX models primarily use nude, severe combined 
immunodeficiency (SCID), or non-obese diabetic (NOD)/SCID mouse strains that have 
compromised immune systems126. We know that the immune system plays a massively 
important role in tumor progression127,128, so this workaround introduces an important 
disadvantage to this system. There have been efforts to re-introduce components of the 
human immune system in either these immune-deficient mice or in previously immune-
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competent mice that have been depleted of their marrow through irradiation. These models, 
called humanized mouse (HM) models, are able to successfully grow transplanted tumor 
cells, but it is unclear how well they truly model a human immune system129,130.  
 Another disadvantage to CDX, PDX, and HM models is that cancer cells have 
already developed in their own separate environment from which experimentation will take 
place, either established in culture for many passages or derived from human patients. The 
extracellular matrix and surrounding tissues and cells change drastically as tumors progress 
in vivo, so the subsequent growth or metastasis of the transplanted tumor cells into a different 
tissue type likely will not be indicative of what would happen with a tumor that seeded and 
developed in the body from one or a small number of precursor cells131–135.  
 The advancement of GEM models addresses this issue by predisposing mice to 
specific cancers by editing their genome to produce cancer-causing mutations, allowing for 
the study of cancer as it develops within the body of the model organism. This method more 
accurately models both primary tumor growth and metastasis because tumor cells are 
confined by their native environment as opposed to being injected at large numbers into a 
tissue without the natural ECM and stromal modification, or intravenously which skips the 
important steps of initial invasion and intravasation136. There are a wide variety of strategies 
for mutating the genome of mice, but they can be broadly split into two categories: 
constitutive and conditional137. Constitutive GEM models introduce systemic mutations to 
the genome that are pervasive throughout time and space from germline through death. While 
this may be useful in some cases to identify early stages of disease onset, the pervasiveness 
of the genetic modifications limits the understanding of the mutation of interest in cancer 
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since the genetic alteration may cause alternate behavior in surrounding tissues that impact 
disease progression independent of the impact of the tumor itself.  
 The second category of GEM models, broadly called conditional GEM models, limits 
the spatial and/or temporal manifestation of the mutation, often through the Cre-Lox system 
of recombination138. Cre is an enzyme that deletes the genomic region of DNA between two 
LoxP nucleotide sites, which are generally employed systemically in all somatic cells during 
genetic modification. However, this process can be spatially controlled by regulating the 
expression of Cre only in the cell types of interest through use of strategic and tissue-specific 
promoters. The Flp-TRP system of recombination works in a similar fashion and is also used 
for conditional GEM modeling137. 
 Cre-Lox recombination can also be controlled temporally by the addition of 
conditional activation of the Cre enzyme. Fusion of the mutated ligand binding domain of the 
human estrogen receptor to Cre (Cre-ER) deactivates the enzymatic activity of Cre until 
introduction of the ligand 4-hydroxytamoxifen (4-HT)139. 4-HT is typically administered 
orally for delivery to various tissue types. However, application of 4-HT to the skin of mice 
is capable of penetrating the outer epidermis to activate Cre-ER in cells at the epidermis 
basal cell layer140 as well as in melanocytes residing in the same area141. Combining the 
spatial and temporal activation of recombination using Cre-ER provides tight regulation and 
reproducibility of tumor induction for careful study of cancer.  
 Properly designed GEM models are vital for uncovering whole-organism phenotypes 
of disease, though they can pose a major challenge for the understanding of the mechanisms 
driving these changes. Pairing microscopy with live mouse models to visualize cancer cells 
within their native environment has proven to be a difficult feat due to high background, 
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tissue autofluorescence, bleaching, and inability to penetrate deep into the tissue. These 
barriers to studying cancer cells were first overcome in 2000 with the use of two-photon 
intravital imaging to study breast cancer cells expressing green fluorescent protein (GFP) 
injected into the fat pad of rats136. Using this technique, the authors were able to analyze the 
motility of cells within the primary tumor as well as identify changes in polarization and 
relative location to vasculature. Two-photon imaging cuts down drastically on 
photobleaching and background while achieving deeper penetration into the tissue, so the 
target area of the tumor was able to be successfully visualized for long periods of time. 
 This breakthrough in two-photon intravital imaging laid the groundwork for the 
development of our lab’s own intravital imaging system. We first used two-photon 
microscopy to visualize spheroids of melanoma cells that were orthotopically injected into 
the ears of nude mice to form a tumor142. Mice were anesthetized with isoflurane and the ears 
were stabilized using a custom aluminum clamp during imaging. Using two-photon 
microscopy we were able to optimize three-channel imaging, including one channel of 
extracellular second harmonic signal generation from the bundled collagen to visualize tumor 
cells interacting with surrounding ECM. Improving on this system, our lab has developed 
multiple GEM models to study cells in their native environment141,143,144. Two of these 
systems that utilize the Cre-ER system of recombination for tightly regulated tumor induction 






CHAPTER 2: NEW MECHANISMS OF RESISTANCE TO MEK INHIBITORS IN 
MELANOMA REVEALED BY INTRAVITAL IMAGING1
Introduction 
Activating mutations in the MAPK pathway drive malignant transformation in 
melanoma, with BRAF(V600E) being the most common driver in patient settings145–147. 
Clinical use of selective MEK and BRAF inhibitors (MEKi and BRAFi) have extended 
overall survival in patients with BRAF-mutant melanoma57,59,148. Although initially effective, 
resistance to these targeted therapies eventually develops, even in patients given combined 
BRAFi/MEKi therapy60,148,149. A number of mechanisms have been suggested for how 
melanoma can become refractory to therapy, including increased PI3K and AKT pathway 
activity, enhanced expression of receptor tyrosine kinases (e.g., c-KIT, FGFR, and EGFR), 
and compensation for BRAF activity through NRAS mutation or CRAF or ARAF 
upregulation150–152. Despite this work, there exists a substantial need for relevant preclinical 
models to analyze therapeutic response in vivo in order to make better prognostic predictions 
and to inform treatment strategies153.  
A complex variety of genomic, epigenetic, and extracellular factors all affect how 
melanoma responds to and resists therapeutic intervention. Evidence of “phenotype 
 
1Brighton, H. E. et al. New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital 
Imaging. Cancer Res 78, 542–557 (2018).  
I am a middle author on this manuscript and provided some tumor measurements and animals for drug study. 
However, the vast majority of this research was done by the first author, Hailey Brighton. This chapter is 
included because it provides a base understanding of the mouse models and some techniques used in Chapter 3. 
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switching” at the molecular level has also been identified as a relevant mechanism for how 
tumors become resistant to targeted therapy154–156. Via this mechanism, tumor cells may 
adapt a stem-like phenotype, and a “switch” from epithelial to mesenchymal phenotype has 
been documented in a variety of tumors in response to drug, which is thought to promote 
malignancy and therapy resistance157. 
Melanoma cell heterogeneity, which is driven by both switches in molecular 
expression and changes in the extracellular microenviroment, also influences therapeutic 
resistance158,159. Exactly how the extracellular matrix (ECM) affects tumor response to drug 
remains unclear. It is known that collagen in tumors is commonly cross-linked in linear 
bundles, which can stiffen the microenvironment and elicit downstream signaling events that 
promote tumorigenesis160,161. Improving our understanding of how therapeutics influence the 
ECM within the tumor microenvironment is critical, as collagen deposition and 
reorganization may promote melanoma cell invasion, malignancy, and resistance through 
multiple mechanisms162,163. Furthermore, intratumoral regions with high stromal cell 
concentrations have been shown to promote tumor cell persistence against BRAF inhibitor164. 
Modeling ECM behavior in tumor development and drug response through proper in vivo 
strategies can help uncover new therapeutic approaches and targets165. 
To address the challenges of modeling response and resistance to targeted therapies, 
we have extended an existing Tyr::CreER; BRAFCA;PTENlox/lox (PBT) genetically 
engineered murine (GEM) model of melanoma by crossing in a Lox-Stop-Lox tdTomato 
fluorescent reporter allele (tdTomatoLSL;166,167). The incorporation of this allele enables 
direct tracking of endogenous melanoma development and therapeutic response over time 
through noninvasive intravital imaging. With a highly localized application method of 4-
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hydroxytamoxifen (4-HT) on the mouse ear, we have achieved precise spatiotemporal control 
of melanoma initiation. Using this approach, we directly visualized tumor and collagen 
reorganization throughout development and response to single-agent trametinib (a highly 
potent, allosteric MEKi;168) and trametinib/dabrafenib combination MEKi/BRAFi therapy. 
We also identified changes in molecular behavior through transcriptome and kinome 
reprogramming analysis at early and late stages on therapy, providing a comprehensive view 
of melanoma response to MAPKi. 
Results and Discussion 
Specific 4-HT application method enables spatiotemporal control of tumor growth 
Although inducible GEM models of cancer have enhanced our understanding of 
tumor biology and therapeutic response, there exists a significant need to improve these 
models for translational research169. The ability to control endogenous tumor initiation in 
time and space is a critical experimental variable that needs to be improved to better model 
melanoma as it occurs in patients. We developed a precise induction method, where 1 μL of 
20 mmol/L 4-HT was applied to the middle of the mouse ear for 8–10 minutes then carefully 
removed and the area washed. We chose to induce melanoma on the ear because the skin of 
the mouse ear contains a population of intrafollicular melanocytes that more closely mirrors 
human skin, and the ear provides an ideal surface for stable intravital imaging169,170. Our 
imaging strategy incorporated a tdTomato fluorescent reporter allele (tdTomatoLSL) in the 
existing tamoxifen-inducible PBT melanoma GEM model (Fig. 1A;166,167). This method of 4-
HT application yielded robust local tumor formation on mouse ears in a reproducible fashion; 
tumors forming with 100% penetrance (Fig. 1B; Supplementary Fig. S1). In addition, precise 
spatiotemporal control of melanoma induction in this GEM model extended animal lifespan 
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(normally limited by multiple primary tumors), which enabled long-term longitudinal in vivo 
studies of melanoma development and, later, drug response. 
Visualizing the process of endogenous tumor progression from early stages has been 
a relative “black box” in the field, as most existing models cannot be used to track tumor cell 
behavior over time at cellular resolution. We used two previously described intravital 
imaging methods to interrogate tdTomato+ PBT melanoma behavior both at the macroscopic 
(mm) and microscopic (μm) scale using a stereomicroscope and a multiphoton microscope, 
respectively (Supplementary Fig. S1A and S1B;142). Using anesthetized animals, we 
positioned them on a heating pad and stabilized the ear with a custom designed ear clamp 
during imaging. With multiphoton imaging, we were able to quantify the original number of 
recombined melanocytes postinduction. Less than 2 days after 4-HT treatment, we identified 
individual recombined endogenous melanocytes within the dermis (Supplementary Fig. S1). 
At this stage, we counted the tdTomato+ melanoma cells in a 1.2-mm2 region (140 
cells/mm2) and approximated the total number of recombined cells that are initially induced 
by extrapolating from the average area of the 4-HT droplet (2.77 mm2, n = 20; 
Supplementary Fig. S1C and S1D). We identified different populations of recombined 
tdTomato+ cells, including both intra- and interfollicular melanocytes within the dermis, and 
calculated less than 400 melanocytes initially recombined in this system with 20 mmol/L 4-
HT to yield reproducible tumor formation (Supplementary Fig. S1E and S1F). 
Next, we imaged PBT melanoma progression from early stages serially over time to 
characterize melanoma development in this model. Tracking tumors each week post-4-HT 
application via transmitted light and fluorescence imaging revealed stages of tumor growth 
that were reproducible from tumor to tumor at different time points (Fig. 1C). At the 
 
 25 
macroscopic level, melanoma initially spread radially, forming a palpable tumor mass within 
6–8 weeks postapplication of 4-HT, and we observed relatively homogeneous tdTomato 
distribution throughout tumor growth, even in separate cohorts (Fig. 1D, data not shown). 
Melanoma growth, measured by tumor depth, was exponential, and there was no evidence of 
tumor development in other regions on the animal (Fig. 1E; Supplementary Fig. S1G). 
Furthermore, breeding out the Ptenlox/lox and BRAFCA alleles yielded a control 
Tyr::CreER; tdTomatoLSL mouse line for comparison with nontumorigenic fluorescent 
melanocytes, which were dendritic and did not proliferate to form melanoma (Supplementary 
Fig. S2A).  
Figure 2.1 Genetic incorporation of 
tdTomato enables visualization of 
melanoma initiation and growth 
with specific 4-HT application 
method. 
A, Diagram of PBT 
(Tyr::CreER;BRAFCA;PTENlox/ 
lox;tdTomatoLSL) melanoma GEM 
model pre- and post- CreER-induced 
recombination. B, Macroscopic 
images pre-, during, and post-4-HT 
application on a single mouse ear. 
Olympus MVX10. Scale bar, 500 mm. 
C and D, Macroscopic images with 
transmitted light (C) and tdTomato 
fluorescence (D) of tumor growth 
longitudinally over time on a single 
mouse ear, 2 to 9 weeks post-4-HT 
application. E, Tumor growth, 
measured by tumor depth, over time; 






Longitudinal intravital imaging reveals distinct phases of melanoma development. 
Multiphoton imaging provided a platform to simultaneously visualize tdTomato+ 
melanoma cells and second harmonic generation (SHG), which enabled detection of the 
bundled collagen fiber network in the tumor microenvironment171. Using the SHG as a guide, 
we visualized the tumor cells throughout the dermis (depth range of 30–200 μm), between 
the epidermis and the cartilage layer in the middle of the mouse ear. In addition, we 
identified known structures such as hair follicles, which are evident by their circular structure 
and a center devoid of fluorescence. 
By tracking the tdTomato+ melanoma cells in concert with the SHG, we followed 
melanoma development from early stages with cellular resolution, and we identified distinct 
phases of growth (Fig. 2A; Supplementary Fig. S2B). During the “proliferation phase,” the 
first few weeks post-4-HT application, we identified clonal populations of melanoma cells 
arising directly in the dermis. These regions of concentrated tdTomato+ cells expanded over 
time to become densely packed pretumorous lesions. From there, tdTomato+ cells spread 
radially throughout the dermis, during the “pre” (2–4 weeks) and “early tumor” (4–6 weeks) 
phases, where the dermis became dense with tdTomato+ melanoma cells. During this phase, 
SHG signal was significantly reduced, suggesting degradation of bundled collagen and the 
ECM. Here, we also clearly identified the tumor boundary in the ear at the cell level 
(Supplementary Fig. S2C, white line). Finally, the “late tumor phase” (7+ weeks), 
corresponded with the vertical growth phase in patient settings, as melanomas rose above the 
original flat surface of the ear (Figs. 1D and 2A). Fluorescence intensity analysis at these 
different stages of tumor development further recapitulated our ability to model clinical 
tumor growth, as tdTomato increased and SHG signal decreased over time (Fig. 2B and C). 
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To compare our ad hoc intravital staging series to more traditional approaches, we 
used classic histology techniques to characterize tumor progression in this model via 
hematoxylin and eosin staining. Consistent with our intravital imaging, tissue thickness 
increased over time, and infiltration of stromal cell populations and increased tumor cell 
concentrations were evident (Fig. 2D). Masson's trichrome (MT) staining further 
demonstrated the degradation of collagen post-4-HT application (Fig. 2E). Because the 
tdTomato signal was conserved after tissue processing for histology, we also performed 
fluorescence microscopy of histologic sections to visualize tumor development at different 
phases (Fig. 2F; Supplementary Fig. S2D). With this technique, in the “proliferation phase,” 
we saw a small population of tdTomato+ cells on the dorsal part of the mouse ear where 4-
HT was applied. In the early and late tumor phases, however, we identified vertical growth in 
both ventral and dorsal regions of the ear, and at the “late tumor phase,” we identified 





Figure 2.2. Visualizing melanoma development over time with cellular resolution. 
A, Intravital multiphoton images of tdTomatoþ PBT melanoma development in the mouse 
ear over time; 0–9 weeks postapplication of 20 mmol/L 4-HT. SHG reveals bundled collagen 
within the dermis of the ear. Images show merged SHG and tdTomato channels. 
FV1000MPE; 1,050 nm; 4% laser power. Normalized average intensity of tdTomato signal 
(B) and SHG signal during tumor growth over time (C); N = 12. Error, 95% CI. Hematoxylin 
and eosin staining (D) and MT staining (E) of mouse ears 2, 6, and 8 weeks post-4-HT 
application. Olympus BX51; 10x objective; brightfield. F, Histology of tdTomatoþ tumor 
growth at 2, 6, 7, and 8 weeks postapplication of 20 mmol/L 4-HT. Images display merged 
DAPI and tdTomato channels. Olympus BX51; 20x objective. 
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Through defining distinct phases of melanoma development in situ from the initial 
time point, our system provides a mechanism to visualize tumor cell behavior in a variety of 
different investigative platforms. We envision that this system can be used to interrogate 
distinct and relevant hallmarks of early tumor behavior in vivo, such as tumor angiogenesis, 
tumor–stroma interactions, and invasion prior to vertical growth172. However, because our 
main objective was to create a model of long-term patient response to therapy, we used this 
system to probe the longitudinal effects of the selective MEK1/2 inhibitor on melanoma 
behavior at the cellular and molecular levels. 
Melanoma response to MEKi over time is heterogenous  
Standard of care for treating activated BRAF-mutant melanoma includes combination 
BRAFi (e.g., dabrafenib) and MEKi (e.g., trametinib) therapy58. Mechanisms of resistance to 
BRAF inhibitors have been extensively characterized in both GEMs and humans. Herein we 
have focused on the response to the selective allosteric MEK1/2 inhibitor, trametinib 
(hereafter referred to as MEKi), which effectively inhibits both Ras and BRAF activation of 
the ERK pathway168. To investigate how targeted MEKi therapy affects tumor behavior at the 
macroscopic and cellular levels in this model, we fed MEKi-containing chow to mice 8 to 9 
weeks post-4-HT application, beginning at the late tumor phase, and serially imaged 
melanoma response to drug using intravital imaging. MEKi was incorporated into chow 
(Research Diets) with a daily dose of 0.3 mpk, and food intake was calculated using the 
Jackson Laboratory's Phenome Database, as in previous studies173. Because tumor 
development is spatiotemporally controlled in our model, we were able to extend drug 
treatment and visualize both PBT melanoma response to MEKi and tumor regrowth (after 12 
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weeks on MEKi), mimicking extended tumor resistance to targeted therapy in patient 
settings. 
Without drug treatment, tumors grew exponentially in a spatially defined region with 
relatively homogenous tdTomato expression throughout continued growth, compared with 
heterogeneous response over time on MEKi (Fig. 3A and B). All tumors responded quickly 
on MEKi treatment, however, with approximately 30% reduction in tumor size within the 
first week compared with control (Fig. 3C and D). Given enough time on therapy, disease 
progressed and tumors regrew, returning to their original size within 12 weeks. Tumor 
response was heterogeneous even at the macroscopic level, with some regions of persistent 
tdTomato signal and other regions devoid of fluorescence, which were re-populated with 
tdTomato+ cells at late stages on MEKi (Fig. 3B, arrows). These results suggest evidence for 
both intrinsic and acquired functional resistance to MEKi in this model and mimic 




Figure 2.3 Heterogeneous tumor response and epithelialization on MEKi over time. 
Macroscopic images of a PBT tumor without drug treatment 8, 9, 10, 14, and 16 weeks post-
application of 20mmol/L 4-HT (A) and macroscopic images of a PBT tumor over time pre- 
and 1, 5, 10, and 12 weeks on trametinib therapy (B). Graphical representation of PBT tumor 
thickness/growth over time without MEKi trametinib treatment (C) and over time on MEKi 
therapy; N = 4. Error ¼ 95% CI (D). Widefield images of IHC of PBT tumors pre-, at 1 week 
(early) and 7 weeks (late) on MEKi, stained with vimentin (E) and E-cadherin (F). Olympus 
FV1000, open pinhole; 20x. 
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MEKi induces epitheliazation and intratumoral reorganization 
We sectioned tumors at early and late stages on MEKi for histology and discovered 
decreased expression of vimentin, a mesenchymal marker, as well as an increase in E-
cadherin via IHC (Fig. 3E and F). We also found changes in tumor cell organization and 
melanin expression over time through brightfield and fluorescence imaging (Supplementary 
Fig. S3A and S3B). Before drug treatment, tumor cells aggregated within the dermis but 
aligned with elongated and spindle-like morphologies closer to the cartilage boundary 
(Supplementary Fig. S3C, top). Early on MEKi, we identified intratumoral nests within the 
dermis, where tumor cells organized in a dense circular fashion (Supplementary Fig. S3C, 
middle). Tumor nests have been described as growth-promoting regions in melanoma, and at 
this stage on MEKi, they may indicate structures that promote therapeutic resistance174. 
There was also a reduction in tdTomato+ cells near the cartilage layer. At the late stage on 
MEKi during tumor regrowth, tumor nests were less obvious in the dermis, with a 
reemergence of melanoma cells again near the cartilage boundary (Supplementary Fig. S3C, 
bottom). Interestingly, tumor nests were only identified in regions of invasion through the 
cartilage boundary at the late stage on MEKi (Supplementary Fig. S3D). The density of 
tdTomato+ melanoma was enhanced in the late MEKi stage compared with pretreatment, 
demonstrating that tumor regrowth was largely due to tumor cells themselves 
(Supplementary Fig. S3). 
Tumor cells colocalize with bundled collagen during initial survival on MEKi 
The ECM in tumors is highly dynamic, and deregulation of collagen crosslinking 
within the ECM has been shown to play a causative role in cancer pathogenesis175,176. We 
used our multiphoton intravital microscopy system to identify critical changes and 
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dependencies between tumor cells and bundled collagen between early and late stages on 
MEKi. Before therapy, SHG signal was low, reflecting a loss or degradation of ECM in PBT 
tumors 9 weeks post-4-HT. However, MEKi treatment caused morphologic changes and 
reorganization of tumor cells as early as 3 days on drug (Fig. 4A). Strikingly, tdTomato 
strongly colocalized with SHG during this phase, suggesting that the bundled collagen within 
the dermis of the ear played a role in tumor cell survival on MEKi (Fig. 4A and B). After 
several weeks of continuous treatment, this spatial correlation between tumor cells and 
bundled collagen structures remained strong (Fig. 4A and B). Furthermore, the tdTomato+ 
melanoma cell density increased over several weeks on MEKi, demonstrating microscopic 
tumor persistence prior to tumor regrowth. 
In the late stage on MEKi (6–12 weeks), the correlation between tumor cells and 
bundled collagen structures diminished as the tumor regrew (Figs. 3D and 4). At this stage, 
we observed a loss in spatial correlation and colocalization between tdTomato and SHG 
signals, and we identified regions of tumor cells independent of collagen and vice versa (Fig. 
4A, arrows). Through colocalization analysis between tdTomato and SHG signal, we were 
able to measure this loss in tumor cell association with bundled collagen over time on MEKi 
(Fig. 4B). This suggests that over time, as MEKi loses efficacy and melanoma becomes 
resistant, bundled collagen structures become less critical for tumor cell survival, which may 
be due to a significant change in tumor signaling or phenotype. 
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Figure 2.4 Intravital 
imaging reveals a 
relationship 
between bundled 
collagen and tumor 
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1,050 nm; 4% power. 
Scale bar, 50 mm. B, 
Average Pearson 
correlation 
coefficients for SHG 
and tdTomato signals 
over time on MEKi 
treatment; N = 9. 
Error, 95% CI. C, 
MT staining of 
histologic slices of 
PBT melanoma at 
early and late time 
points (1 and 7 
weeks) on MEKi. 
Blue signal represents 
intratumoral ECM 
and bundled collagen. 
 
 
Classical IHC staining by hematoxylin and eosin and MT revealed that ECM deposition was 
greatly enhanced in the late stage compared with early on MEKi (Fig. 4C and D, blue stain). 
This suggests bundled collagen may play a significant role in tumor cell survival during the 
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beginning of trametinib therapy. Although the ECM changed in character (deposition, 
location, concentration, distribution, organization), and bundled collagen increased during 
MEKi treatment, the dependency on bundled collagen for tumor cell survival at the 
individual cell level diminished as treatment continued, indicating a plastic relationship 
between ECM and tumor growth during drug response. 
Kinome profiling of the MEKi response revleals potent and durable MEK1/2 inhibition and 
adaptive kinome reprograming 
Because we were able to visualize changes in drug response at the tumor cell level 
over time by intravital imaging, we sought to complement these insights by interrogating the 
molecular changes that occur over time on MEKi (Supplementary Fig. S4). To identify 
reprogramming events in the kinome in parallel with our imaging studies, we harvested 
MEKi-treated and control tumors and performed molecular analysis of tumor response. We 
used a chemical proteomics approach (multiplexed-inhibitor bead affinity chromatography 
coupled with MS, MIB/MS) to assess the state of the kinome in our model. The adaptive 
response to targeted kinase inhibitors can lead to dramatic alterations in signaling and 
ultimately to drug resistance and tumor progression177–179. We have previously used MIB/MS 
to characterize the adaptive response leading to therapeutic resistance to MEK inhibition in 
triple-negative breast cancer and lapatinib in HER2+ breast cancer180,181. The affinity 
purification involves a mixture of type I kinase inhibitors to selectively enrich for kinases 
based on their activation state, abundance, and affinity for the inhibitors. Untreated tumors 
and tumors from mice treated for 1 week (early) or 12 weeks (late) on MEKi were harvested, 
snap-frozen, and processed for MIB/MS (Fig. 5A). As predicted, loss of MEK1/2 MIB 
binding (as determined by LFQ intensity) was dramatic compared with untreated control 
tumors and persisted throughout the duration of the experiment (Fig. 5B). The MIB binding 
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loss of BRAF and ERK1/2 was also readily observed by LFQ intensity (Supplementary Figs. 
S5A–S5C). These observations confirmed that tumors from the trametinib-treated mice 
displayed MEK inhibition coincident with the overall tumor depth decrease. 
To gain insight into the global kinome response to MEK inhibition, the kinome data 
were processed with Perseus software and hierarchical clustering of the log2-transformed 
LFQ intensities was performed (Fig. 5C). Notably, the majority of kinases exhibited a 
comparative loss of binding in response to trametinib related to the growth arrest and tumor 
shrinkage (Fig. 5C, inset). Despite the potent inhibition of MEK, a subset of kinases 
displayed a pattern of increased MIB binding over time. These kinases included the RTKs c-
KIT and Ephrin type-A receptor 1 (EPHA1), the metabolic kinase FN3K, PTK6, the stress-
associated kinase CDK5, and B lymphoid kinase (BLK). Although a degree of tumor 
heterogeneity could be observed in the untreated and early time points, the late group 
appeared more similar in global kinome behavior. This observation was corroborated by 
principal component analysis of the kinome profile (Supplementary Fig. S5D). To visualize 
the magnitude and significance of the kinome changes, volcano plots were generated for the 
early and late MEKi-treated tumors relative to the untreated control group (Fig. 5D and E). 
As expected, we saw significant loss in MIB binding of MEK1 and MEK2. In contrast, 
kinases such as c-KIT, FGFR3, and BLK were most dramatically increased in response to 
MEKi. These observations were confirmed via Western blot analysis of tumor lysates (Fig. 
5F), including loss of phospho-ERK1/2 and a decrease in total PDGFRβ. In addition, 
tdTomato levels were comparable across all of the tumors by Western blot analysis 
(Supplementary Fig. S5E). These experiments demonstrate the feasibility of chronologic 
kinome evaluation in our melanoma model and demonstrate the plasticity of the kinome, 
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even in response to a potent and selective MEKi. The adaptive kinome response allows a 
reprogramming of melanoma signaling for the onset of resistance to MEKi. 
 
Figure 2.5. Adaptive kinome response to chronic and potent MEK inhibition. 
A, Schematic representation of experimental MIB/MS workflow. B, MIB binding (LFQ 
intensities) for MEK1 and MEK2 from untreated, early, and late tumors. ***, P < 0.001. C, 
Hierarchical clustering displayed as a heat map of mean-centered, log2-transformed LFQ 
intensities (MIB binding) from untreated, early, and late tumors as in A. Select panels are 
indicated and labeled with kinases by row. D, Volcano plot showing log2-fold change MIB 
binding (LFQ intensity) for early versus untreated tumors plotted against the –log10 P value 
(FDR ¼ 0.05). Dotted line, P ¼ 0.05. E, Volcano plot showing log2-fold change MIB 
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binding (LFQ intensity) for late versus untreated tumors plotted against the –log10 P value 
(FDR ¼ 0.05). Dotted line, P ¼ 0.05. F, Western blots for untreated, early, and late tumors as 
in A. ERK2 was used as a loading control. 
 
Transcriptome analysis reveals a phenotypic state change with enhanced epithelial signature 
in response of MEKi 
To assay changes in gene expression throughout MEKi treatment, we utilized sections 
of snap-frozen tumors harvested at early and late time points of drug treatment for RNA-seq 
analysis and compared expression changes with the adaptive kinome response, measured by 
MIB/MS. As shown in Fig. 6A, hierarchical clustering of kinome gene expression in 
response to MEK inhibition revealed substantial and distinct changes at both early and late 
time points compared with untreated tumors. To identify differentially expressed kinases, we 
performed DESeq2 comparing the early and late time points to control tumors and visualized 
the genes in volcano plots182. After one week on MEKi, the expression of numerous kinases 
was dramatically altered (Fig. 6B). Expression of Mek1/Map2k1 and Mek2/Map2k2 was 
significantly decreased with Mek1 levels reduced more significantly than Mek2. Other 
kinases with diminished expression included the poorly characterized serine/threonine kinase 
Stk32a, Cdk18, Akt3, Epha3, and Alk. In contrast, the tumors harvested after 1 week of 
treatment displayed increased expression of the fibroblast growth factor receptors Fgfr2 and 
Fgfr3, as well as Rps6ka1 (p90Rsk) and Ddr1, which we have observed in previous in vitro 
studies181. 
At the late time point, Mek1/Map2k1 and Mek2/Map2k2 were not significantly 
altered (Fig. 6C). In contrast, the expression of kinases including Cdk18, Alk, Akt3, and 
Stk32a was reduced more significantly and to a greater degree over the course of trametinib 
treatment. Another kinase with increased gene expression at the late time point included 
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Ntrk1, neurotrophic receptor tyrosine kinase, which is important for neuronal development 
and survival and may play a similar role in melanoma183. In addition, expression of the 
nonreceptor Src-related tyrosine kinase Srms, thought to play a role in keratinocyte 
proliferation, was increased at the late time point (Fig. 6). Distinct from the early time point, 
the expression of lymphocyte kinases Itk and Zap70 was increased with MEK inhibition. 
Collectively, chronic treatment with MEKi led to tumor persistence and regrowth that 





Figure 2.6. Transcriptome profiling reveals dramatic mesenchymal-to-epithelial 
phenotypic shift in response to trametinib. 
A, RNA-seq analysis of untreated, early, and late tumors as log2-transformed RSEM 
normalized gene counts. Hierarchical clustering displayed as a heat map of the mean-
centered mouse kinase genes. B, Volcano plot showing log2-fold change (RNA-seq) for early 
versus untreated tumors plotted against the –log10-adjusted P value (FDR ¼ 0.05) as 
determined by DESeq2. Dotted line, P ¼ 0.05. C, Volcano plot showing log2-fold change 
(RNA-seq) for late versus untreated tumors plotted against the –log10-adjusted P value (FDR 
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¼ 0.05) as determined by DESeq2. Dotted line, P ¼ 0.05.D, Log2 LFQ intensities (MIB 
binding) and log2 RNA-seq expression changes (early vs. untreated) are plotted for kinases 
quantified by MIB/MS. E, Log2 LFQ intensities (MIB binding) and log2 RNA-seq 
expression changes (late vs. untreated) are plotted for kinases quantified by MIB/MS. F, 
RNA-seq data from untreated, early, and late tumors were used for pathway signature 
analysis and clustered. Representative signatures from each cluster are indicated at right. G, 
Log2-fold change as determined by DESeq2 for select genes involved in EMT. H, Volcano 
plot as in B for transcription factor genes. I, Volcano plot as in C for transcription factor 
genes. J, Western blots for indicated proteins from untreated, early, and late tumors. 
 
To directly compare the MIB/MS kinome profiles with RNA-seq expression data, we 
plotted the fold-changes observed in kinome by each assay (Fig. 6D and E). At both the early 
and late time points, the inhibition of Mek1 and Mek2 was almost exclusively 
pharmacologic, as determined by loss of MIB binding. In contrast, the loss of Cdk18, Epha3, 
Epha7, and Stk32a was observed at the transcript level correlating with loss of functional 
MIB binding. The RTKs Met and Epha1 were found to increase by both RNA-seq and MIB 
binding, whereas expression of the RTK Kit was only significantly increased in the early 
stage but displayed sustained functional MIB binding throughout the course of MEKi 
treatment (Fig. 6D and E). The B lymphocyte kinase, Blk, exhibited increased binding at the 
late time point but no change in gene expression. Together, the RNA-seq and kinome data 
indicate a transcriptional reprogramming of the kinome that results in an adaptive change in 
functional kinases demonstrated by the ability to capture kinases with MIBs. 
As an additional approach to global analysis, we used pathway analysis of gene 
expression signatures (35). Using a panel of previously published gene signatures derived 
from human transcriptional profiles, pathway signature scores were derived from the mouse 
tumors using the shared Homologene ID (Fig. 6F). Clustering of the pathway signatures 
readily illuminated five distinct patterns of pathway activity (Fig. 6F; Supplementary Figs. 
S6A–S6D). High pathway signature scores for cluster 1 (related to mammary stem cells, 
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basal-type breast cancer, and fibroblasts) were observed in the untreated control tumors but 
not in MEKi-treated tumors. Thus, the tumors appeared to shift from mesenchymal-like to 
epithelial-like expression patterns after 1 week on MEKi. In addition, signature scores for 
pathways associated with immune response (e.g., T-cell, B-cell, CD8) increased in response 
to MEKi, and indicative of prosurvival signaling, PI3K and AKT pathway scores were also 
increased over time. Despite some heterogeneity observed in each group, the signature scores 
for EMT_up and EMT_down were decreased and increased, respectively, over time on 
MEKi. Thus, the global pathway analysis corroborated the persistent survival of tdTomato+ 
tumor cells and supported a shift to an epithelial state and immune response during treatment. 
As the pathway analysis suggested a transcriptional response to an epithelial 
phenotype, we explored the relative expression levels of a subset of epithelial-mesenchymal 
transition (EMT)-associated genes (Fig. 6G). Genes associated with epithelial phenotype, 
such as E-cadherin, were significantly increased in response to MEKi whereas those 
associated with mesenchymal phenotype were reduced. Changes in these EMT-associated 
genes were sustained during MEKi therapy in the early and late treatment groups. Gene list 
enrichment analysis by Enrichr reinforced this finding, as genes significantly upregulated at 
early and late time points were most enriched in the “Epithelium” gene set for Mouse Gene 
Atlas (Supplementary Figs. S6E-TRAMETINIB). 
Given the dramatic changes in the transcriptome observed in our model in response to 
MEKi, we surmised that lineage-specific transcription factors might drive the observed 
phenotypic shift. Therefore, we investigated the mouse transcription factors as a discrete 
gene subset (Fig. 6H and I). The Sox family of transcription factors are critical players in 
neural crest development and have been implicated in melanomagenesis184,185. In response to 
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MEKi, we observed a significant upregulation of Sox21 and downregulation of Sox5 and 
Sox10. Furthermore, two of the most significantly altered transcription factors at both time 
points were Zeb1 and Grhl2 (Grainy-head-like 2). Interestingly, Zeb1 and Grhl2 have been 
demonstrated to participate in an intricate reciprocal regulatory feedback loop that governs 
EMT in breast cancer186. As the transcriptome analysis indicated a shift to an epithelial-like 
phenotype in the persistent tumors, we performed immunoblotting and confirmed that E-
cadherin (CDH1) and pan-Cytokeratin increased in response to MEKi (Fig. 6J). 
Analysis of the transcriptome revealed that the adaptive kinome reprogramming and 
collagen reorganization occur in concert to promote persistence of melanoma cells for long-
term survival on MEKi. In addition, although EMT has been characterized as a potential 
mechanism for resistance to BRAFi, our gene expression analysis suggests the opposite, with 
increased epithelial signatures in drug-treated tumors compared with control. 
Modeling BRAFi and MEKi combination therapy 
Although these studies focus on the singular effects of MEK inhibition, we also 
utilized the combinatorial treatment of dabrafenib and trametinib that has provided more 
durable clinical responses when compared with BRAFi alone. Intravital imaging of tumors 
on BRAFi/MEKi combination therapy revealed a similar pattern in stromal collagen 
plasticity; however, regions of collagen independent of tumor cells were visualized as early 
as 2 weeks on drug treatment (Fig. 7A). As anticipated, treatment with BRAFi/MEKi caused 
tumor shrinkage, similar to MEKi alone, but with sustained and prolonged growth inhibition 
(Fig. 7B). 
Untreated tumors and tumors treated for 1 week (early) or 5–12 weeks (late) with 
BRAFi/MEKi were harvested. By MIB/MS analysis of the functional kinome, treated tumors 
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segregated in response to BRAFi/MEKi (Fig. 7C; Supplementary Fig. S7A and S7B). MEK 
inhibition was consistently observed (sufficient unique peptides for BRAF were not detected 
for quantification) and numerous RTKs exhibited increased binding—Ddr1, Met, Ptk6, 
EphA1 (Supplementary Fig. S7A–S7B). However, the early and late treatment groups for 
BRAFi/MEKi were less distinguishable from one another by principal component analysis 
than in response to MEKi alone (Supplementary Fig. S7C). This observation was consistent 
with the reported durability of combined BRAF and MEK inhibition and with the significant 




Figure 2.7. Combined inhibition of MEKi and BRAFi also reveals an EMT_down 
signature and kinome reprogramming in persistent melanoma. 
A, Intravital multiphoton imaging of tdTomatoþ PBT melanoma response to BRAFi/MEKi 
combination pretreatment and at early (5 days), intermediate (2 weeks), and late (11 weeks) 
stages on drug. Maximum intensity projections; FV1000MPE; 25x; 1,050 nm; 4% power. 
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Scale bar, 50 mm. B,Graphical representation of PBT tumor thickness over time with and 
without BRAFi/MEKi treatment over time. N = 6, except 12-week N ¼ 2. Error, 95% CI. C, 
Hierarchical clustering displayed as a heat map of mean-centered, log2-transformed LFQ 
intensities (MIB binding) from untreated, early, and late tumors as in Fig. 6A. D, Log2 LFQ 
intensities (MIB binding) and log2 RNA-seq expression changes (early vs. untreated) are 
plotted for kinases quantified by MIB/MS. E, Log2 LFQ intensities (MIB binding) and log2 
RNA-seq expression changes (late vs. untreated) are plotted for kinases quantified by 
MIB/MS. F, RNA-seq data from untreated, early, and late tumors were used for pathway 
signature analysis and clustered. Representative signatures from each cluster are indicated at 
right. F, Western blots for untreated, early, and late tumors as in A. ERK2 was used as a 
loading control. 
 
RNA-seq was also performed on tumor samples, and dramatic alterations in kinome 
expression patterns were observed (Fig. 7D and E; Supplementary Fig. S7D). The kinome 
expression changes were compared to the MIB/MS kinome profiles. Although MEK1 and 
MEK2 displayed significant loss of MIB binding consistent with MEKi treatment with 
minimal change in expression, kinases including Ddr1, Fgfr2, and Ptk6 exhibited increased 
expression levels in parallel with enhanced functional MIB binding in response to 
BRAFi/MEKi. As with single-agent MEKi, analysis of transcription factor expression in 
response to BRAFi/MEKi revealed increased Grhl2 and decreased Zeb1 expression and 
dynamic shifts in the expression of Sox transcription factors (Supplementary Fig. S7E and 
S7F). Pathway signature analysis of the RNA-seq data substantiated the phenotypic shift 
toward a more epithelial-like phenotype (decrease in EMT_up signature over time) and 
evidence of immune infiltration (increase T-cell signature) (Fig. 7F). Western blots from 
mouse melanoma tumors indicated that treatment with BRAFi/MEKi led to an expected 
decrease in phospho-MEK1/2 not seen with MEKi alone. Although BRAF and phospho-
MEK1/2 levels rebounded at the late time point, signaling to phosphoERK1/2 was not fully 
restored, consistent with the loss of MEK MIB binding. 
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To validate our observation of alterations in EMT factors and Sox lineage 
transcription factors, we examined clinical data and human melanoma cell lines. Analysis of 
clinical data in which patients received BRAFi or BRAFi/MEKi revealed that the Sox family 
of transcription factors are highly dynamic EDT and at progression in response to MAPK 
pathway inhibition (Supplementary Fig. S7G). Furthermore, analysis of a panel of human 
melanoma cell lines exhibited heterogeneity at baseline and in their response to 
BRAFi/MEKi in EMT markers, Sox transcription factors, and RTKs (Fig. 7G). Our model 
exhibited behavior strongly similar to the human cell line SK-MEL-100—an RTK response 
involving c-Kit and a shift toward an epithelial-like phenotype, highlighted by increased 
expression of E-cadherin and decreased Beta-catenin. Collectively, these data reinforced our 
findings with single agent MEKi that the tumors underwent adaptive changes to combined 
BRAFi/MEKi over time and displayed phenotypic changes and persistent survival. 
Discussion 
We developed a highly localized 4-HT application method in an inducible GEM 
model that achieved reproducible spatiotemporal control of melanoma development on the 
mouse ear. We reproducibly tracked melanoma development from initial stages through 
advanced tumorigenesis, and then used long-term longitudinal studies to study tumor 
response to therapy, closely mimicking clinical response in patient settings. 
Our intravital imaging approaches allowed us to observe tumorigenesis from the 
single cell stage in vivo. We identified several reproducible phases of melanoma 
development. Early on, we visualized the development of clonal populations of melanoma 
cells directly in the dermis, which became densely packed pretumorous lesions that spread 
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radially throughout the dermis, as it occurs in humans. By 2 months post-4-HT application, 
melanoma grew vertically within the dermis to form palpable and spatially defined tumors. 
Through long-term longitudinal studies on MEKi in our melanoma model, we 
discovered that intratumoral reorganization of melanoma cells and bundled collagen, along 
with enhanced expression of epithelial markers, played a significant role in tumor cell 
survival on drug. The SHG signal tightly correlated with tdTomato+ cells at early treatment 
stages, suggesting a model of dependency on bundled collagen for initial tumor cell survival. 
In the late stage on MEKi, however, this correlation was abrogated, with heterogenous 
regions of melanoma cells present independent of collagen; graphically represented in 
Supplementary Fig. S8. Structural intratumoral differences at different stages on drug, like 
the presence of tumor nests in regions of invasion across the cartilage boundary at the late 
stage on MEKi, could support protective mechanisms that enable long-term survival on drug. 
In addition, although direct interaction with bundled collagen matrix was reduced in the late 
stage on MEKi, there is more collagen within tumors at this stage overall, compared with 
pretreatment. These results suggest that the stiffening of tumors due to enhanced collagen 
deposition and tumor cell reorganization over time may promote resistance to targeted 
therapy. 
Furthermore, spatiotemporal control of tumor growth enabled us to perform a 
longitudinal and comprehensive view of molecular plasticity on drug in vivo. Analysis of our 
MIB/MS data revealed enhanced activity of the collagen binding receptor DDR1 at the early 
stage on MAPKi, promoting the idea that collagen promotes tumor cell survival against 
therapy. Although phenotype switching via “EMT” has previously been described as a means 
to promote drug resistance; instead, we find evidence that “MET” progression appears to 
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enhance survival of melanoma against MAPKi. Notably, a novel “keratin-high” and 
epithelial-like subclass of melanoma that correlated with poor prognosis was recently 
described by the TCGA analysis of human cutaneous melanoma187. Comparing mRNA-seq 
and MIB/MS data of melanoma tumors in late versus early stages on drug, we have identified 
c-KIT, EPHA1, CDK5, BLK, PTK6, and FGFR2/3 as potential drivers of functional 
resistance to MEKi in this model. These finding were recapitulated in combination 
BRAFi/MEKi-treated tumors and consistent with the heterogeneity of responses seen in 
patients and human cell line models. 
By using a combination of novel approaches in our model system, we set the stage for 
new discoveries and understanding about tumor biology and therapeutic response. Coupling 
our imaging studies with transcriptome and kinome reprogramming analysis enables direct 
interrogation of tumor plasticity in vivo during drug response and identification of properties 
and potential therapeutic targets that promote resistance. Using these novel approaches, we 
have developed a model that enables direct observation of endogenous tumor development, 
tumor heterogeneity, and plastic response to targeted therapy at the endogenous cell level in 
situ. These methods will advance our basic understanding of the cellular processes involved 
in disease progression, increase the utility of existing and future GEM models, and aid in the 
testing of new therapeutics for malignant melanoma. 
Materials and Methods 
Local 4-HT application method 
All animal studies have been conducted in accordance with guidance from the Institutional 
Animal Care and Use Committee at University of North Carolina-Chapel Hill (Chapel Hill, 
NC). To achieve spatially controlled melanocyte recombination by local topical application, 
we applied 1 μL of a 20 mmol/L concentration of 4-HT solution in DMSO, 100% ethanol, 
and orange-6 dye to allow precise visualization of the region exposed to 4-HT, in which 
CreER is activated (Sigma-Aldrich), to the middle of the ear while the mouse was 
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anesthetized. After 8 to 10 minutes, the area was vigorously washed with 70% EtOH to 
prevent transfer of tamoxifen to other areas and to ensure a single, controlled primary lesion 
(Fig. 1B). Using this method, we consistently induced local melanoma growth exclusively in 
the applied region in a reproducible fashion. 
Intravital two-photon microscopy 
Tumor-bearing animals with tumors between 10 and 30 mm3 were imaged as previously 
described142. Animals were anesthetized with 1% to 2% isoflurane on a heating pad equipped 
with temperature feedback, and tumors were imaged before and during the course of drug 
treatment studies. All imaging was performed on an Olympus FV1000MPE with an Insight 
DeepSee IR laser (Spectra-Physics) and an upright BX-61WI microscope, using a 25×, 1.05 
NA (2 mm TRAMETINIB.D.) water immersion objective with optical imaging gel with the 
same refractive index as water to capture images. Laser was tuned to 1,050 nm to excite 
tdTomato fluorescence. A custom aluminum ear clamp, with (i) a bottom platform on which 
the ear rests and (ii) an upper piece equipped with a pair of thumbscrews to secure the ear 
underneath a coverslip, facilitated transfer of heat to the ear from an underlying heating 
plate/pad during imaging. Laser power (4%), software, and microscope settings (RXD2 and 
RXD4 channel PMT voltages at 850 and 500, respectively) were consistent for all acquired 
images. Two channel non-descan detectors were used for image collection, and data were 
gathered with the Olympus Fluoview software. 
Macroscopic imaging of tdTomato positive tumors 
 Macroscopic imaging was performed on an Olympus MVX10 macroscope system, and 
images were collected using Metamorph software and a color camera at ×0.8 or ×1 
magnification. Fluorescent images were acquired using a mercury lamp and filter wheel for 
red fluorescence. Mice were anesthetized with 1% to 2% isoflurane and placed on a heating 
pad during imaging. Ears were flattened and stabilized to 5-mL tubes with double-sided tape 
to enable full macroscopic view of each tumor. 
Histology of tumor progression and tumor response to trametinib 
Ears and lymph nodes were excised and fixed in 4% paraformaldehyde at 4°C for 24 hours. 
Tissues were then cryoprotected with fresh 30% sucrose at 4°C for 24 hours. Ears and lymph 
nodes were then frozen in VWR Clear Frozen Section Compound (VWR 95057) using an 
ethanol/dry ice bath and were stored at −80°C before sectioning. Sectioning and hematoxylin 
and eosin staining were performed by the Cell Biology & Physiology Histology Core at 
University of North Carolina-Chapel Hill. 
Drug treatments and further mouse protocols 
A total of 0.3 milligrams per kilogram (mpk) trametinib (GSK212) powdered compound or, 
for combination studies, 0.3 mpk trametinib + 18 mpk dabrafenib powdered compound 
mixture was added to a base mixture, which was added to normal food/chow mixture before 
being pelleted by Research Diets, Inc. Prepared chow was fed to mice, which were harvested 
at 1 and 12 weeks on drug treatment. Tumor measurements were performed with a digital 
caliper every week during the course of each experiment, and measurements for length, 
width, and height were recorded (in mm). Tumor size was indicated by tumor depth. Mice 




Fluorescence intensity analysis 
Maximum intensity projections were made from z-stacks with 4-μm intervals, taken with 
FV1000MPE two-photon, (roughly 20–40 slices per image, depending on tumor depth). 
Average intensity was measured using Metamorph software analysis, and the intensity for 
each image was normalized by subtracting the value for background average fluorescence. 
Measurements were averaged for each time point, post-4-OHT application, plotted in Excel, 
and graphed in Prism. Each image was acquired with 4% laser power to maintain 
consistency. 
Multiplexed inhibitor bead chromatography and mass spectrometry 
Snap-frozen tumors were crushed by mortar and pestle in ice-cold multiplexed inhibitor bead 
(MIB) lysis buffer (50 mmol/L HEPES, 150 mmol/L NaCl, 0.5% Triton X-100, 1 mmol/L 
EDTA, 1 mmol/L EGTA, pH 7.5) supplemented with complete protease inhibitor cocktail 
(Roche) and 1% phosphatase inhibitor cocktails 2 and 3 (Sigma). Extracts were sonicated 3 × 
10 seconds, clarified by centrifugation, and syringe-filtered (0.22 μm) prior to Bradford assay 
quantitation of concentration. Equal amounts of total protein (0.3 mg) were gravity-flowed 
over MIB columns in high salt MIB lysis (1 mol/L NaCl). The MIB columns consisted of 
175-μL mixture of six type I kinase inhibitors (CTx-0294885, VI-16832, PP58, Purvalanol B, 
UNC-21474, and UNC-8088A) custom-synthesized with hydrocarbon linkers and covalently 
linked to ECH-Sepharose (or EAH-Sepharose for Purvalanol B) beads as previously 
described180. Columns were washed with 5 mL of high salt (1 mol/L NaCl), 5 mL of low salt 
(150 mmol/L NaCl) MIB lysis buffer, and 0.5 mL low-salt lysis buffer with 0.1% SDS. 
Bound protein was eluted twice with 0.5% SDS, 1% β-mercaptoethanol, 100 mmol/L Tris-
HCl, pH 6.8 for 15 minutes at 100°C. Eluate was treated with DTT (5 mmol/L) for 25 
minutes at 60°C and 20 mmol/L iodoacetamide for 30 minutes in the dark. Following spin 
concentration using Amicon Ultra-4 (10k cut-off) to approximately 100 μL, samples were 
precipitated by methanol/chloroform, dried in a speed-vac and resuspended in 50 mmol/L 
HEPES (pH 8.0). Tryptic digests were performed overnight at 37°C, extracted four times 
with 1 mL ethyl acetate to remove detergent, dried in a speed-vac, and peptides further 
cleaned using C-18 spin columns according to manufacturer's protocol (Pierce). 
RNA isolation, RNA-seq library preparation, RNA-seq, and analysis 
A center section of each snap-frozen tumor was excised with a clean razor blade and RNA 
isolated using the RNeasy Plus Mini Kit (Qiagen) according to manufacturer's protocol with 
the optional DNase I treatment (Qiagen) for 15 minutes. Four hundred nanograms of total 
RNA was used as input for RNA-seq library construction with a Kapa Stranded mRNA Kit 
according to the manufacturer's protocol. TruSeq adapter sequences were used for indexing. 
Library amplification was as described with 12 PCR cycles. Equimolar amounts of each 
library were run as multiplexed1.65 pM pools, single-indexed, on a NextSeq 500–75 cycle, 
high output V2 Kit. QC-passed reads were aligned to the mouse reference genome (mm9) 
using MapSplice188. The alignment profile was determined by Picard Tools v1.64. Aligned 
reads were sorted and indexed using SAMtools and translated to transcriptome coordinates 
and filtered for indels, large inserts, and zero mapping quality using UBU v1.0. Transcript 
abundance estimates for each sample were performed using an expectation–maximization 
algorithm, RSEM189. Expected read counts for genes were used as input for DESeq2 to 
identify differentially expressed genes182. Differentially expressed gene sets (Padj < 0.1) 
 
 52 
were used as input for Enrichr190,191 to identify pathway enrichments. Heat maps of log2-
transformed RSEM normalized expression values were generated using GENE-E software 
(Broad Institute). Normalized RSEM mouse gene values were converted to unique human 
gene IDs by shared Homologene ID. Pathway signatures were determined as previously 
described192,193. 
Cell lines and drug treatments 
The human melanoma cell lines used, A375, SK-MEL-190, WM266-4, SK-MEL-100, SK-
MEL-5, and Mel537, have been extensively characterized194. Cells are routinely tested for 
mycoplasma contamination by DAPI staining and passaged no more than 1 month prior to 
experiments. Cells were cultured in DMEM (A375, WM266-4) or RPMI (SK-MEL-190, SK-
MEL-100, SK-MEL-5, and Mel537) supplemented with 10% FBS and 1% penicillin–
streptomycin. Dabrafenib and trametinib were purchased from Selleck and dissolved in 
DMSO. Cultures were treated with DMSO as control or with 100 nmol/L dabrafenib and 10 
nmol/L trametinib in combination for 48 trametinib. 
Western blotting 
Snap-frozen mouse tumors or human melanoma cell lines were extracted in MIB lysis buffer 
(150 mmol/L NaCl) as above and filtered lysates were boiled in 1× SDS sample buffer for 10 
minutes at 100°C. Equal amounts of lysate were separated by SDS-PAGE, transferred to 
nitrocellulose membrane, blocked with 5% milk in TBS, and subjected to immunoblotting 
with the following primary antibodies: PDGFRβ, DDR1, phospho-ERK1/2 (218/222), 
MEK1/2, phospho-MEK1/2, SOX2, and E-cadherin, from Cell Signaling Technology; pan-
Cytokeratin, BRAF, c-Kit, SOX10, and ERK2 from Santa Cruz Biotechnology; RFP (to 
detect tdTomato) from Rockland; SOX21 from ProteinTech. Secondary antibodies used were 
goat anti-rabbit-HRP or goat anti-mouse-HRP from Pierce Biotechnology. SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific) was used and images were collected 
on a Bio-Rad ChemiDoc. 
Liquid chromatography, mass spectrometry, and analysis 
Peptides were resuspended in 2% ACN and 0.1% formic acid. Forty percent of the final 
peptide suspension was injected onto a Thermo Easy-Spray 75 μm × 25 cm C-18 column and 
separated on a 180 minutes gradient (5–40% ACN) using an Easy nLC-1000. The Thermo Q 
Exactive mass spectrometry (MS) ESI parameters were as follows: 3e6 AGC MS1, 80 
milliseconds MS1 max inject time, 1e5 AGC MS2, 100 milliseconds MS2 max inject time, 
20 loop count, 1.8 m/z isolation window, 45 seconds dynamic exclusion. Raw files were 
processed for label-free quantification (LFQ) by MaxQuant LFQ using the Uniprot/Swiss-
Prot mouse database and default parameters were used with the following exceptions—only 
unique peptides were used, matching between runs was utilized, and phospho-STY peptides 
were included. Normalized LFQ intensities were log2-transformed and hierarchical 
clustering (1−Pearson correlation) performed using GENE-E or imported into Perseus 
software. In Perseus, LFQ intensities were log2-transformed, missing values were imputed 
from the matrix if at least three valid values were present in at least one treatment group, and 





Analysis of SOX transcription factor expression  
Normalized, log2-transformed expression data (GSE99898) from patient samples 
pretreatment, early during treatment (EDT), or at progression on dabrafenib, vemurafenib, or 
dabrafenib and trametinib was retrieved from the Gene Expression Omnibus (GEO; 195). 
Log2 difference in gene expression for the SOX transcription factors was determined relative 
to pretreatment for each matched patient sample and hierarchical clustering was performed 
























up acquired with 
iPhone6. C) 1µl 
4-HT droplet, 
approximately 





region of the 
mouse ear. E) SHG, tdTomato, and Merge max. intensity projections of the dermis 40hours 
post-4-HT. Arrows mark single melanocytes. Olympus FV1000MPE; 1050nm; 4% laser 
power. Bar = 50μm. F) Panel of macroscopic images with transmitted light of 20 different 
tumors, all 9 weeks post-4-HT. 18 tumors used in this study, 2 from separate cohort. Bar = 
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FV1000MPE; 25X; 4% power. Scale bar = 50μm. B) Two-photon max intensity projections 
of PBT tumor development over time at 1, 3, 5, 7 and 9 weeks post-application of 20mM 4-
HT. Bar = 50μm. C) Merge of SHG and tdTomato at tumor boundary in mouse ear, 4 weeks 
post-4-OHT application. FV1000MPE; 1050nm; 25X; 4% power. Bar = 50μm. D) Histology 
of PBT mouse ears 4 days and 2, 6, 7, and 8 weeks post-application of 20mM 4-HT. 
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S2.4. MEKi Experiment 
Overview.  
Graphical representation of 
the experimental design for 
longitudinal treatment and 
molecular analysis of 
melanoma response at early 
and late stages on 
continued treatment with 
MEKi (0.3mpk), compared 
to no drug control. Orange 
dots in (1) represent 4-HT 
application, circular shapes 
represent no drug control 
(gray) and MEKi treated 
(blue) tumors. 6 tumors for 
each condition (no drug 
control, early, and late on 
MEKi) were harvested for 
molecular profiling. 
MIB/MS and mRNA-seq 
images are representative of 
results from this experiment 





Supplementary Figure S2.5. (untitled).  
(A, B, and C) MIB binding (LFQ intensityies) for (A) BRAF, (B) ERK1 and (C) ERK2 from 
untreated, early, and late tumors described in Fig. 5A. ***, p<0.001 (D) Principal component 
analysis of log2(LFQ intensity) for kinases identified by MIB/MS in untreated and early and 
late MEKi-treated tumors. (E) Immunoblotting to detect tdTomato expression from tumor 






Supplemental Figure S2.6. mRNAseq pathway signature analysis reveals gene 
expression reprogramming on MEKi.  
Classification of gene expression profile (A and B) and pathway activity signatures (C and 
D) using the principal component analysis (PCA) (A and C) and Silhouette Analysis (B and 
D) between untreated (black), 1 week MEKi (early, red) samples, and 12 weeks MEKi (late, 
green). (E-H) Up-regulated differentially expressed genes (cut-offs of log2FC ≥1 and 
padj≤0.05) determined by DESeq2 were used to query Enrichr for gene list enrichment 
analysis. The bar plots for GO Biological Process 2015 (E and G) and Mouse Gene Atlas (F 






Supplemental Figure S2.7. Kinome and transcriptome responses to combined BRAF 
and MEK inhibition in murine tumors, patient samples, and human cell lines.   
(A) Volcano plot showing log2 fold-change MIB binding (LFQ intensity) for early versus 
untreated tumors plotted against the –log10 p-value (FDR=0.05). Dotted line, p=0.05.  (B) 
Volcano plot showing log2 fold-change MIB binding (LFQ intensity) for late versus 
untreated tumors plotted against the –log10 p-value (FDR=0.05). Dotted line, p=0.05. (C) 
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Principal component analysis of log2(LFQ intensity) for kinases identified by MIB/MS in 
Untreated and Early and Late Dabrafenib/Trametinib-treated tumors. (D) RNAseq analysis of 
Untreated, Early, and Late tumors as log2-transformed RSEM normalized gene counts. 
Hierarchical clustering displayed as a heatmap of the mean-centered mouse kinase genes. (E) 
Volcano plot showing log2 fold-change (RNAseq) for Early versus Untreated tumors plotted 
against the –log10 p-value (FDR=0.05) as determined by DESeq2. Dotted line, p=0.05.  (F) 
Volcano plot showing log2 fold-change (RNAseq) for Late versus Untreated tumors plotted 
against the –log10 p-value (FDR=0.05) as determined by DESeq2. Dotted line, p=0.05. Zeb1 
and Grhl2 are indicated in red, Sox family transcription factors are indicated in blue. (G) 
Normalized gene expression data (GSE99898) was downloaded from GEO.  Patients were 
treated with Vemurafenib, Dabrafenib, or Dabrafenib plus Trametinib.  Tumor samples were 
obtained pre-treatment, early during treatment (EDT) or at progression (Prog). The relative 
change in expression compared to patient matched pre-treatment sample was determined for 
the Sox family of transcription factors and hierarchical clustering was performed using 
Morpheus. (H) BRAF mutant human melanoma cell lines were treated with DMSO as a 
control or with the combination of 100nM Dabrafenib and 10nM Trametinib for 48 h. 






Supplemental Figure S2.8. Graphical representation and model of results.  
Representation of tumor growth and response to MEKi at the macroscopic, cellular and 
molecular levels. Representation of tdTomato+ melanoma and bundled collagen during 
tumor different phases of development and at early, intermediate, and late stages on MEKi. 
And illustrated diagram of key molecular hits that undergo plastic response over the course 
drug treatment. Graphic is based on intravital imaging, MIB/MS, and mRNAseq of 




CHAPTER 3: CORONIN 1C INHIBITS MELANOMA METASTASIS THROUGH 
REGULATION OF MT1-MMP-CONTAINING EXTRACELLULAR VESICLE 
SECRETION2
Introduction 
Melanoma is the deadliest form of skin cancer with a high propensity for metastatic 
spread51,196. The most common genetic drivers of melanoma are BRAF-activating mutations 
such as V600E, often found in conjunction with loss of tumor suppressors such as 
PTEN48,49,197. If caught in its early stages, melanoma is treatable by surgical resection, but 
prognosis worsens significantly with the occurrence of in-transit, regional, or distant 
metastasis. Clinically, up to 54% of metastatic melanoma patients show tumor dissemination 
to the brain, 77% to the liver, and 85% to the lung54. The high rate of metastasis in melanoma 
is poorly understood, but may be linked to lineage-specific factors that impact vesicular 
trafficking, secretion, degradation, and overall cell migration81,85. 
The extracellular matrix (ECM) is an important substrate for tumor cell migration, but 
it also acts as a physical barrier whose degradation by matrix metalloproteinases (MMPs) is 
thought to be a critical step in tumor dissemination198–200. MMPs are a family of both 
transmembrane (designated “membrane-type” or “MT”) and secreted catalytic enzymes 
capable of cleaving ECM proteins and other substrates. Membrane-type 1 matrix 
metalloproteinase (MT1-MMP) is a particularly important pro-invasive MMP across many 
 
2Tagliatela, A. C. et al. Coronin 1C inhibits melanoma metastasis through regulation of MT1-MMP-containing 
extracellular vesicle secretion. Sci Rep 10, 11958 (2020) 
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cancer types104 whose expression closely correlates with invasion and metastasis105,116,201. 
MT1-MMP is also unique in its ability to both directly cleave a wide range of ECM proteins 
including collagen types I, II, and III, laminin 1 and 5, and fibronectin, as well as activate 
pro-MMP2202.  
The trafficking of MT1-MMP to and from the plasma membrane (PM) and other 
membrane structures is surprisingly complex, but critical for the protein’s function during 
tumor invasion and metastasis. Phosphorylation of the cytoplasmic tail initiates 
internalization of MT1-MMP from the PM by both clathrin-mediated and caveolin-mediated 
routes201. Internalized vesicles traffic through the endolysosomal pathway, resulting in 
redirection to other areas of the PM or to the lysosome for degradation203. MT1-MMP 
recycling has been shown to involve various flotilins204 and SNARE proteins110,205–207, as 
well as a variety of Rab proteins including Rab5, Rab7110,204, Rab8106,208, and Rab27a209. 
Interestingly, MT1-MMP can also localize to secreted extracellular vesicles (EVs) and these 
EVs are capable of degrading matrix at sites distant from the cell112,205. The mechanism of 
MT1-MMP trafficking to EVs is not well understood, nor is the significance of this 
phenomenon for metastasis clear. 
Coronins are highly conserved F-actin binding proteins that regulate actin dynamics 
through multiple mechanisms including ADF/cofilin-mediated turnover and Arp2/3 complex-
mediated branching8,9. Coronin 1C is a member of the Type 1 coronin family that has been 
implicated in lamellipodial protrusion, cell migration and, most recently, vesicular 
trafficking29. In pancreatic β-cells, Coronin 1C regulates endocytosis of insulin granule 
membranes and subsequent retrograde transport210. Coronin 1C also plays a role in endosome 
fission to membrane contact sites on the endoplasmic reticulum33, and directly binds to the 
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melanosome- and endosome-sorting protein Rab27a in pancreatic β-cells31. Unlike other 
coronin genes, Coronin 1C expression is highly dynamic and is regulated through 
transcriptional control, as well as through miRNAs25,41,211. Coronin 1C is upregulated in 
several cancers21,36,37,212,213, and its depletion by RNAi has been shown to inhibit 
proliferation, migration, and transwell invasion in lung-squamous cell carcinoma211 and 
triple-negative breast cancer cells25. However, its role in cancer progression has not been 
rigorously tested in animal models of metastatic cancer and has not been functionally tested 
in melanoma at all.  
Animal models of cancer are important tools for studying tumor cell behavior in 
physiological contexts, and genetically engineered mouse (GEM) models allow for the study 
of tumor progression in the presence of an intact immune system. However, GEM models 
have been difficult to use to study metastasis due to lack of control over the site and timing of 
tumor initiation. Recently, we modified an existing GEM model of melanoma by adding a 
Cre-inducible TdTomato fluorescent reporter allele141. Using this model, we developed a 
precise tumor initiation protocol using localized trans-dermal application of 4-
hydroxytamoxifen to activate CreER expressed only in endogenous melanocytes. The 
TdTomato allele in this model allows primary tumors to be tracked by intravital imaging and 
disseminated cells to be detected by fluorescence-based methods such as flow cytometry. By 
combining this model and tumor initiation protocol with a conditional knockout allele, we 







Pten/Braf melanoma tumors lacking Coronin 1C grow faster and metastasize more frequently 
To test the role of Coronin 1C in melanoma growth and metastasis, we modified an 
existing GEM model by breeding in a Coronin 1C conditional knockout allele (Fig. 3.1A). 
The PBT model utilizes Cre/Lox recombination to delete the tumor suppressor gene Pten and 
constitutively activate the oncogene Braf in melanocytes167. The addition of a 
LoxP/stop/LoxP (LSL) TdTomato allele166 enables the tracking of induced tumor cells via 
fluorescent microscopy141 (Fig. 3.1B). The expanded model (designated PBT-1C) utilizes a 
previously validated conditional knockout allele of the Coro1C gene214, allowing us to 
directly compare tumor growth and metastases with and without Coronin 1C.  
Primary tumors were induced on the ears of mice using a previously developed 
topical tamoxifen application protocol141 to activate CreER expressed in the mouse’s 
endogenous melanocytes using the Tyrosinase promoter. Primary PBT-1C tumors (lacking 
Coronin 1C) grew to a palpable mass four to five weeks after induction with tamoxifen, 
while it took approximately six to eight weeks for a palpable mass to form in the PBT 
animals (Fig. 3.1C). Over the course of 13 weeks, primary tumors lacking Coronin 1C grew 
deeper into the tissue significantly faster than their PBT counterparts (Fig. 3.1D). 
Multiphoton imaging of the TdTomato+ tumor cells and the bundled collagen fibers 
(visualized via second harmonic imaging) within the ear revealed that the tumor cells 
increased in number faster when they lacked Coronin 1C, and that the collagen fibers 
degraded more quickly than the PBT control tumors (Fig 3.1E-F). In addition, 
immunohistochemical staining of the primary tumors revealed stronger CD31 staining 
around blood vessels in PBT-1C primary tumors (Sup. Fig. S3.1) suggesting increased 
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angiogenesis215–217. Although there was a trend of larger blood vessels measured in PBT-1C 
tumors at 10 weeks post-induction compared to the control PBT counterparts, this change 
was not significant.   
 
Figure 3.1. Coronin 1C-null melanoma grows faster than endogenous-expressing 
tumors. 
A) Schematic diagram of two GEM models, PBT and PBT-1C. Upon 4-hydroxytamoxifen 
application, CreER expressed under the melanocyte-specific Tyrosinase promotor excises the 
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DNA between LoxP sites, denoted with red triangles, resulting in Pten deletion, BRAF 
constitutive activation and TdTomato expression. In the PBT-1C model, Coro1C is also 
deleted. B) Transillumination and red fluorescence for TdTomato imaging of a PBT-1C 
primary tumor 8 weeks after induction with 4-hydroxytamoxifen. C) Transillumination of 
one PBT primary tumor and one PBT-1C primary tumor over a 12-week period following 
induction. D) Quantification of the mean thickness +/- 95% CI of the ear and primary tumor 
(N of 15 for PBT and N of 16 for PBT-1C. E-F) Representative multi-photon imaging of 
second harmonic signal of the bundled collagen layer and TdTomato expression in 
recombined melanocytes in the primary tumor of a PBT mouse ear (E) and a PBT-1C mouse 
ear (F) over an 8-week period post induction with 4-HT. Scale bars = 50 µm. 
 
To measure metastasis, five organs relevant to clinical melanoma metastasis were 
then checked for the presence of TdTomato+ surface metastases by imaging with a dissection 
microscope (Fig. 3.2A-B). To our surprise, we observed that the Coronin 1C-null tumors in 
the PBT-1C mice had more large, distant metastases (macro-metastases) than the control 
tumors in the PBT model (Fig. 3.2C). While PBT mice displayed no visible metastases to the 
brain or the liver, PBT-1C mice displayed macro-metastases in 18% and 9%, respectively. 
7% of PBT mice and 5% of PBT-1C mice had macro-metastases in the lung.  
Given the fact that the primary tumors grew faster in the PBT-1C mice, we suspected 
that metastastic tumors in distant organs in this model would also grow faster and would 
produce the observed trends in macro-metastases, even without differences in the rates of 
metastatic seeding. In order to address this question, we exploited the presence of TdTomato 
fluorescence in the model to develop a protocol using flow cytometry to identify micro-
metastases that were either too small to see on the dissecting microscope or buried within the 
tissues (Fig. 3.2A). We postulated that the presence of micro-metastases would reflect events 
of metastatic seeding without the confounding factor of tumor growth. Although both the 
PBT and PBT-1C models showed micro-metastases, they were more prevalent in PBT-1C 
mice than PBT in every organ sampled with the exception of the pancreas (Fig. 3.2D), 
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suggesting that in addition to primary tumor cell proliferation, metastatic seeding was also 
enhanced by the deletion of Coronin 1C. The most pronounced differences in the rate of 
micro-metastases were in the brain and liver, where 37.5% and 50% of PBT-1C mice 
developed micro-metastases, respectively, compared to 8.3% and 16.6% in the PBT mice. 
Together, these data show that deletion of Coronin 1C from the tumor cells in this model 
leads to significantly accelerated primary tumor growth and a trend toward enhanced 
metastasis. 
 
Figure 3.2: Loss of Coronin 1C in melanoma results in more distant metastases. 
A) Schematic diagram of macro- and micro-metastasis identification in mouse models. 
Organs are removed and macro-metastases are identified with a stereo microscope via 
TdTomato signal. Organs are then dissociated to a single cell suspension and micro-
metastases are identified by FACS sorting. B) Example of a macro-metastasis identified in a 
PBT-1C mouse brain 13 weeks after induction. For comparison is a PBT brain with no 
visible metastases 19 weeks after induction. C) Donut plots displaying the number of mice 
with identified macro-metastases in green compared to the number of mice screened with no 
visible metastases present in blue for each organ in both PBT and PBT-1C mice. The 
fractions in the middle represent the number of organs with macro-metastases over the total 
number of organs screened. D) Donut plots displaying micro-metastases for the brain, liver, 
lung, pancreas, and spleen for both GEM models as described in C. 
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Coronin 1C-null cells display a higher propensity for invasion 
 To better understand the increased trend towards metastasis observed upon loss of 
Coronin 1C, we isolated a Coronin 1C-null cell line (referred to as Null throughout) from a 
macroscopic brain lesion in a PBT-1C mouse. The cells were then stably rescued with 
Coronin1C-GFP and single cell clones were isolated and expanded (Fig. 3.3A, Sup. Fig. 
S3.2). The clone termed Rescue, showed Coronin 1C expression levels similar to those seen 
in a melanoma cell line derived previously from the Pten/Braf model218 containing 
endogenous Coronin 1C (PBT2460). Another clone termed OE (overexpression) had 
expression of Coronin 1C >2x higher than the endogenous level (Fig. 3.3B).  
 We first characterized proliferation rates of these 3 cell lines and found that Null cells 
proliferated more slowly than their Coronin 1C-expressing counterparts in 2D culture (Sup. 
Fig. S3.2). While this observation is in line with Coronin 1C knockdown in other cancer 
types25,211,219, it also indicates that proliferation in vitro does not always accurately predict 
proliferation in the 3D tumor microenvironment. To compare cell motility rates, we used 
single cell tracking and found that OE cells, moved significantly faster than the Rescue and 
Null lines on FN-coated glass (Fig. 3.3C). While this is consistent with previous 2D work 
involving Coronin 1C in other tumor cell lines25,211,220, it also suggests that this assay is a 
poor predictor of in vivo metastasis. To better mimic the endogenous environment of the 
tumor, multicellular spheroids were generated from each of the three cell lines and embedded 
into a 3D collagen matrix. Invasion of the cells into the surrounding gel was observed over 
15 hours (Fig. 3.3D, Sup. Vid. 1-3). Null cells migrated significantly faster than Rescues, and 
OEs moved the slowest (Fig. 3.3E), suggesting that this form of motility more faithfully 




Figure 3.3. Cells lacking Coronin 1C are more invasive than their Coronin 1C-
expressing counterparts. 
A) A Coronin 1C-null cell line (Null) was isolated from a PBT-1C brain metastasis and 
infected with lentiviral Coronin 1C-GFP. This rescue line underwent clonal expansion to 
create one line with endogenous levels of Coronin 1C (Rescue) and one line with 
overexpressed Coronin 1C (OE). B) Western blot of the Null, Rescue, and OE cell lines 
compared to PBT2460, a cell line isolated from a Pten/Braf melanoma tumor with 
endogenous Coronin 1C. Blot is cropped between C1C (Coronin 1C) and GAPDH to 
conserve space. An uncropped blot for each protein can be found in Sup. Fig. 7. C) Mean 
velocities +/- 95% CI of single Null, Rescue and OE cells migrating on 10 µg/mL 
fibronectin-coated glass. Null cell N=81, Rescue cell N=115, OE cell N=99. Total of 3 
biological replicates for each cell line. D) Representative maximum intensity projection 
movie stills from Null, Rescue, and OE cell spheroids embedded in 3D collagen over 15 
hours after embedding. Scale bars = 100 µm. E) Quantification of the mean velocities +/- 
 
 72 
95% CI measured from individual cells invading the matrix around the main spheroid mass 
outlined in D. Null cell N=123, Rescue cell N=88, OE cell N=191. 3 biological replicates for 
each cell line. F) Donut plots displaying the number of nude mice with identified micro-
metastases in green compared to those with no detectable metastasis in blue for the brain, 
liver, and lung dissected from nude mice injected with spheroids of Null, Rescue and OE 
cells after primary tumor ulceration. The fractions in the middle represent the number of 
organs with micro-metastases over the total number of organs screened. *** = P < 0.001. 
  
To ensure that our in vitro results accurately reflect the in vivo phenotypes observed 
in the original GEM mice, spheroids generated from these cells were injected into the ears of 
nude mice142. This is a critical experiment that controls for any differences in GEM strain 
backgrounds that may have contributed to changes in metastatic potential. Upon primary 
tumor ulceration, organs were subjected to the same metastasis identification protocol that 
was used on the GEM mice (Fig. 3.2A). Tumors arising from Null cell spheroid injection 
resulted in brain and liver micro-metastases in 80% and 60% of cases, respectively, whereas 
the occurrence of micro-metastases fell to 25% for these organs in OE cells, with the Rescue 
cells displaying in an intermediate phenotype. This demonstrated a Coronin 1C-dependent 
decrease in metastasis (Fig. 3.3F) that confirms our in vivo metastasis observations in the 
GEM models. Minimal change in lung micro-metastases was observed between the three 
injected cell lines, and there were no macro-metastases observed in any of the nude mice 
injected with any of the cell spheroids, possibly due to faster primary tumor growth rates in 
this immunodeficient background that resulted in faster ulceration and therefore less time for 
the distant tumors to grow. These data, in conjunction with GEM model metastases and 3D 
cell invasion, demonstrate that the loss of Coronin 1C enhances the invasive capacity and 
metastasis of melanoma tumor cells to the brain and liver. It was unexpected to see such low 
numbers of micro-metastases to the lung considering such increase in the brain and the liver. 
These data, along with minimal change in lung metastases in the GEM model upon Coro1C 
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deletion, suggests that Coronin 1C expression impacts the ability for the dissemination of 
metastases to the brain and liver, but not to the lung. 
Coronin 1C-null cells exhibit increased matrix degradation 
 Since Coronin 1C has a role in suppressing migration/invasion in 3D collagen gels 
but not in 2D, we hypothesized that the cells lacking Coronin 1C may be able to degrade the 
matrix more efficiently, a crucial component of 3D migration110,221. To test this hypothesis, 
we plated cells on 2D FITC-labeled collagen matrix for 24 hours to identify sites of 
degradation by the absence of fluorescent signal. All three cell lines formed invadopodia as 
defined by spots of degradation under the cells where a subset colocalized with spots of 
filamentous actin (F-actin)222. While we saw no significant change in the fraction of cells 
containing invadopodia with or without Coronin 1C (Fig. 3.4B), the Nulls contained roughly 
twice as many spots of degradation under the cell body as the Coronin 1C-rescued lines (Fig. 
4C). 
Although Coronin 1C-null cells had more invadopodia under the cell body than the 
Rescue and OE cells, the most striking difference was the number of degradation spots 
distant from the cells (Fig. 3.4A, D). There were over three times more spots of degradation 
outside of the cell border in the Null cells compared to the Rescue and OE cells (Fig. 3.4D). 
One possible explanation for this result would be that Coronin 1C-null cells visit more areas 
of the gel during the experiment through migration, degrading the matrix via invadopodia as 
they moved along. However, the velocity at which the Null cells moved over the gelatin 




Figure 3.4. Coronin 1C null cells degrade gelatin more efficiently than Coronin 1C-
expressing cells. 
A) Null, Rescue and OE cells were plated on FITC-conjugated 2D gelatin matrices for 24 
hours, fixed, and stained for F-actin with phalloidin-568. Black spots in the gel matrix are 
indicative of degradation, and degradative spots of invadopodia that colocalize with actin 
puncta are shown with red arrows.  Scale bars = 25 µm. Zoom = 3.5X. B) Percent of cells 
that contain degraded spots of the matrix beneath the cell body. C) Number of degraded spots 
per cell showing degradation. D) Number of degraded spots per area of 2D matrix 
uninhabited by a cell body. N cells B-C >30 from 3 biological replicates. N of images 
analyzed for D = 30 from 3 biological replicates. E) Mean velocities +/-95% CI of Null, 
Rescue and OE cells migrating on 2D gelatin matrices over 16 hours. N cells > 40 from 3 
biological replicates. F) Null, Rescue, and OE cells were plated on FN-coated glass 
coverslips, fixed, and surface labeled with MT1-MMP. Integrated fluorescence density was 
calculated for individual cells and graphed as mean +/- SEM. N >70 for each cell line over 3 
biological replicates. ** P < .01, *** = P < 0.001.  
 
We therefore postulated that not all of these degradation events observed outside of 
the cell boundary of the Null cells originated from PM-localized invadopodia, but rather from 
a diffusible factor secreted into the extracellular space. To test this hypothesis, we harvested 
conditioned media from each cell line and ran a zymography assay to visualize changes in 
secreted degradative proteins (Fig. 3.5A). We identified a band of gelatin degradation at ~60 
kD that was nearly ten times stronger in the Null cell conditioned media compared to the 
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Rescues and OEs (Fig. 3.5B), demonstrating that the loss of Coronin 1C results in an increase 
in the secretion of degradative factors. 
Extracellular vesicles containing MT1-MMP, Trp1 and Rab27a are responsible for 
extracellular matrix degradation 
We sought to identify the protein in the conditioned media responsible for the 60 kD 
band of degradation. MT1-MMP was a strong candidate due to its molecular weight, 
relevance in cancer invasion, and its unique signature in melanoma120,223–225. Western blot 
analysis revealed higher MT1-MMP expression in the conditioned media from Nulls relative 
to Rescues and OEs (Fig. 3.5C), while MT1-MMP in the cellular lysates were unchanged 
(Fig. 3.5D). To confirm that MT1-MMP localized to distant sites of degradation, we used 
immunofluorescent staining and observed co-localization of MT1-MMP with degraded spots 
both under the cells and at distant sites (Fig. 3.5E). These MT1-MMP-positive sites of 
extracellular degradation also colocalized with extracellular vesicle (EV) markers CD63 (Fig. 
3.5E), HSC70 (Sup. Fig. S3.3), and β1 integrin (Sup. S3.Fig. 3). MT1-MMP (Fig. 3.5F) and 
each EV marker (Fig. 3.5G, Sup. S3.Fig. 3) was also detectible in western blots of pelleted 
EVs following differential ultracentrifugation of the conditioned media in the Null cells 
while these proteins were either decreased or undetectable in the Rescues and OEs. 
Interestingly, we also detected increased MMP2 secretion in the Null cells (Sup Fig. S3.3F) 
and saw localization to sites of degradation, though on the western blot the molecular weight 
of ~75 KD ran higher than where we saw degradation on the zymography gel, and is 




Figure 3.5. Enhanced MT1-MMP secretion coincides with matrix degradation. 
A) Zymography gel of conditioned media from Null, Rescue and OE cells. Black arrow 
highlights band in the Null lane at ~60kd. Loading controlled by cell count at time of 
conditioned media collection. B) Quantification of the band outlined in (A) across 3 
biological replicates. Rescue and OE intensity was normalized to the Null intensity for each 
replicate. C) Western blot of the Null, Rescue, and OE conditioned media probed with MT1-
MMP. D) Western blot of Null, Rescue, and OE whole cell lysates probed with MT1-MMP 
and GAPDH loading control in separate lanes. Blot it cropped to conserve space, uncropped 
blots can be found in Sup. Fig. 7. E) Immunofluorescent images of TdTomato CRISPR 
knockout Null cells plated for 24 hours on 2D FITC-gelatin stained for F-actin with 
phalloidin-568 and immunolabeled with MT1-MMP and CD63. Full-sized image scale bars 
= 5 µm. Zoom image scale bars = 1 µm. F-G) Western blots of EVs pelleted from 
conditioned media at 10,000 x g and 100,000 x g probed for MT1-MMP (F) and CD63 (G). 
H) Mean +/- SEM integrated fluorescent density of PM-bound MT1-MMP after staining with 
MT1-MMP conjugated to AlexaFluor647 without cell permeabilization. N of cells >75 per 
condition across 3 biological replicates. 
 
Since whole-cell MT1-MMP levels were not affected by Coronin 1C expression (Fig. 
3.5D) but were increased on EVs being secreted by Coronin 1C null cells, we tested if MT1-
MMP present on the PM was affected by Coronin 1C expression. To address this question, 
fixed cells were labeled for MT1-MMP presented on the PM using a fluorescent conjugated 
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primary antibody. Integrated fluorescent density was measured for individual cells to 
determine the quantity of MT1-MMP present on the surface. Interestingly, we found that 
PM-localized MT1-MMP increases as the levels of Coronin 1C expression rises (Fig. 3.5H), 
consistent with altered trafficking of MT1-MMP with and without Coronin 1C. These results 
suggest that MT1-MMP secreted on EVs, as opposed to the surface-presented MT1-MMP, is 
driving the degradation at distant sites and subsequent invasion of these cells. 
Based on the evidence of altered secretion in the Coronin 1C-null cells, we sought to 
identify ultrastructural abnormalities indicative of changes in the secretion pathway. 
Transmission electron microscopy (TEM) images were taken of each of the three cell lines. 
The Nulls exhibited many multicompartmental EVs docked at the cell surface, presumably 
for secretion (Fig. 3.6A) and some separated from any surrounding cells (Sup. Fig. 3.4), 
suggesting these structures were being released into the media. By contrast, Rescues and OEs 
displayed fewer EVs docked to the cell surface, and there was a noticeable increase in the 
amount of membrane-bound bodies built up around the PM (Fig. 3.6B-C, Sup. Fig. S3.4). 
Some of these bodies bore resemblance to the EVs at the cell surface, denoted by red arrows, 
and others showed signs of abnormal multivesicular body development, denoted by purple 
arrows. An additional subset of these bodies, highlighted by blue arrows, bore a strong 
resemblance to granular melanosomes226. In cases where we captured EVs being secreted 
from OE cells, they were presented at the end of fingerlike projections (Fig. 3.6D, Sup. Fig. 
S3.4) which strongly resemble a proposed mechanism of melanosome transfer where 





Figure 3.6. MT1-MMP EV secretion overlaps with melanosome secretion pathway. 
A-D) TEM images of cells plated on 2D coated tissue culture dishes. A) TEM of a Null cell 
secreting a multicompartmental EV. B) TEM showing buildup of pigmented vesicles (blue 
arrows) along the PM and what looks to be an MVB not contained by a membrane within the 
cell body (red arrow) of a Rescue cell. C) TEM showing a buildup of pigmented vesicles 
(blue arrows) and abnormal MVBs (purple arrows) along the PM of an OE cell. D) TEM of a 
multicompartmental EV being expressed at the tip of a fingerlike projection in an OE cell. 
Scale bars for A-D = 0.5 µm. E) Airyscan images of Null, Rescue, and OE cells plated on 
FN-coated glass, stained for F-actin with phalloidin-568 and immunolabeled with MT1-
MMP and Trp1. Scale bars for full-sized images = 5 µm. Zoom image scale bars = 1 µm. F) 
Airyscan images of Null, Rescue, and OE cells plated on FITC-labeled gelatin, stained for F-
actin with phalloidin-568 and immunolabeled with MT1-MMP and Trp1. Scale bars for full-
sized images = 5 µm. Zoom image scale bars = 1 µm. 
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These observations show differences in vesicular trafficking and EV secretion 
depending on Coronin 1C expression. We were especially intrigued by the observation of 
melanosome-like structures accumulating near the membrane in the Rescue and OE cells. 
Immunostaining with late-stage melanosome marker Trp1 revealed pockets of strong signal 
near the PM. which colocalized with both MT1-MMP and Coronin 1C in the Rescue and OE 
cells (Fig 3.6E). These pockets of increased PM signal were absent in Null cells, but Trp1- 
and MT1-MMP-postive spots on the glass surface near the cells were observed. On FITC-
labeled gelatin, Trp1 co-localized with sites of degradation along with MT1-MMP in each of 
the three cell lines (Fig. 3.6F). 
To further confirm that this phenomenon is tied to the melanosome secretion 
pathway, we tested the role of Rab27a, a protein critical for the trafficking and docking of 
melanosomes68,230, in MT1-MMP secretion. We found that upon Rab27a inhibition with the 
drug Nexinhib20 which inhibits the interaction with Rab27a and Slp1/JFC1231, extracellular 
degradation was drastically reduced (Sup. Fig. S3.5). Interestingly, Rab27a also localizes to 
spots of extracellular degradation and was detected in the EVs pelleted from Null cell CM 
via western blotting. These data are consistent with the notion that MT1-MMP secretion is at 
least partially utilizing the melanosome secretion pathway, and that this process is affected 
by the presence or absence of Coronin 1C. This melanosome secretion pathway is lineage-
specific, and thus unique to melanoma compared to other cancer types. This observation may 
explain the unexpected increase in metastasis upon the loss of Coronin 1C in this tumor type.  
MT1-MMP is crucial for melanoma cell invasion 
To functionally confirm that MT1-MMP was responsible for surrounding matrix 
degradation, we depleted MT1-MMP using two distinct shRNAs. The resulting knockdown 
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(Sup. Fig. 3.6) correlated with decreased degradation in the zymography assay of Null cell 
conditioned media (Fig. 3.7A). Upon plating the MT1-MMP-depleted cells on 2D gelatin, we 
observed a significant reduction in distant spots of degradation in Rescue and OE cells (Fig. 
3.7B). Strikingly, we observed >tenfold reduction in the number of degradation spots distant 
from the cells in the Nulls with MT1-MMP depletion, and these cells also showed a decrease 
in the percentage of cells containing degradation spots (Fig. 3.7C) as well as a slight decrease 
in the total number of degradation spots under each cell (Fig. 3.7D). Interestingly, MT1-
MMP depletion led to only modest changes in the number of invadopodia of Rescues and OE 
cells suggesting that a baseline level of MT1-MMP-independent invadopodia function exists 





Figure 3.7. MT1-MMP is required for Coronin 1C-null cell invasive phenotype. 
A) Mean +/- SD of intensity of degradation at ~60kd from conditioned media of Null cells 
with and without treatment with two shRNA constructs targeting MT1-MMP, normalized to 
Null cells, for 3 biological replicates. B-D) Null cells with or without treatment with 2 
shRNAs targeting MT1-MMP were plated on FITC-conjugated 2D gelatin matrices for 24 
hours, fixed, and imaged for degradation quantification. B) Number of degraded spots per 
area of 2D matrix uninhabited by a cell body. C) Percent of cells that contain degraded spots 
of the matrix beneath the cell body. D) Number of degraded spots per cell showing 
degradation. N of images analyzed for B-D = 30 from 3 biological replicates. N cells B-D 
>30 from 3 biological replicates. E) Representative maximum intensity projection movie 
stills from spheroids made from Null cells and Null cells treated with 2 shRNAs for MT1-
MMP knockdown embedded in 3D collagen over 15 hours after embedding. Scale bars = 100 
µm. E) Quantification of the mean velocities +/- 95% CI measured from individual cells 
invading the matrix around the main spheroid mass outlined in D. Cell N for each condition 
>40 between 3 separate spheroids. 
 
Upon MT1-MMP depletion we also observed a decreased capacity for Null spheroids 
to invade in 3D collagen (Fig. 3.7E, Sup. Vids. 4-5). The velocities of the Nulls with MT1-
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MMP depletion was reduced to near the levels of the OEs (Fig. 3.7F). MT1-MMP depletion 
in Rescue cells showed slight but significant decrease in 3D cell velocity and no significant 
difference was observed in the MT1-MMP-depleted OE cells. Together, these results show 
that MT1-MMP secretion is critical for melanoma cells to degrade ECM and efficiently 
invade the surrounding matrix. Moreover, these data show that the increased invasion 
observed in Coronin 1C-null melanoma cells is almost entirely dependent on MT1-MMP. 
Discussion 
In this study, we functionally tested the role of Coronin 1C in primary tumor growth 
and metastasis using a Braf/Pten Cre-inducible GEM model for melanoma141. Surprisingly, 
we found that primary tumor growth was accelerated without Coronin 1C (Fig. 3.1) and that 
both macroscopic and microscopic metastatic events were more frequent (Fig. 3.2, 3F). Cells 
isolated from these Coronin 1C-null tumors displayed a greater propensity for invasion in 3D 
collagen matrices compared to cells re-expressing Coronin 1C, consistent with our in vivo 
results (Fig. 3.3, Sup. Vids. 1-3). The Coronin 1C-null cells showed a striking increase in 
secretion of MT1-MMP compared to rescue lines (Fig. 3.5), which is crucial for ECM 
degradation at sites distant from the cells in 2D and for 3D invasion (Fig. 3.7). From these 
observations, we conclude that the loss of Coronin 1C in melanoma leads to increased release 
of MT1-MMP-containing extracellular vesicles, resulting in an increased propensity for local 
tumor cell invasion and, more importantly, for the establishment of distant metastases. 
Because the MT1-MMP-containing EVs colocalize with both exosome markers as well as 
melanosome marker Trp1 (Figs. 3.5-6, Sup. Figs. S3.3, S3.5), we hypothesize that secretion 
of these EVs reflects an aberrant, Coronin 1C-regulated melanosome secretion pathway, and 
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that this mechanism is likely responsible for the unique role of Coronin 1C in melanoma 
invasion.  
MT1-MMP’s role in invasion is well documented and is one of the most important 
MMPs for cancer progression104,105,116,201. The degradative protease activity of MT1-MMP is 
typically thought to function at the PM, with a strong enrichment at invadopodia 
structures49,94. These finger-like protrusions are crucial for tumor cell invasion in vitro and 
are believed to help tumor cells breach the basement membrane and other ECM barriers 
during several stages of metastasis in vivo49,99,136,232. In addition to the pericellular function of 
MT1-MMP at the PM, several studies have also reported that it is secreted into the 
extracellular space on EVs. MT1-MMP can be secreted both on exosomes112,208 as well as on 
microvesicles205 in melanoma cells. In both cases, MT1-MMP maintains the correct topology 
to degrade substrates in the extracellular space. However, the mechanism by which MT1-
MMP is secreted on EVs and how this process is regulated remains poorly understood. 
In our studies, we found extracellular spots of matrix degradation that colocalized 
with MT1-MMP and contained exosome markers CD63, HSC70 and β1integrin (Fig. 3.5). 
While these observations suggest that these MT1-MMP-containing EVs are being released as 
exosomes through an MVB-mediated secretion pathway34,233–235, in actuality the story is 
more complicated as these structures also contain the melanosome markers Trp1 (Fig. 3.6F) 
and Rab27a (Sup. Fig. S3.5). These data, along with the presence of aberrant MVBs and 
multivesicular EVs in our Rescue and OE cells (Fig. 3.6A-D, Sup. Fig. 3.4), suggest that 
secretion of MT1-MMP-containing EVs are regulated by some kind of functional crosstalk 
between the MVB and melanosome trafficking machinery.   
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Melanoma is a uniquely aggressive cancer that has a high propensity for invasion and 
establishment of distant metastases. This behavior is thought to reflect the developmental 
history of melanoblasts/melanocytes. Consistent with this idea, melanoma cells display early-
development gene signatures during tumor progression80,85,236,237 and studies illustrate how 
melanoma cells revert back to gene expression signatures of precursor Neural Crest Cells 
(NCCs) that give them growth and migratory advantages to promote tumor development82,85. 
Interestingly, MT1-MMP is highly expressed in NCCs238 and has recently been identified as 
a necessary contributor to NCC migration239 and these elevated levels of MT1-MMP are 
inappropriately re-expressed in melanoma during disease progression104.  
Vesicular and membrane trafficking are also uniquely regulated in melanocytes and 
have been observed to be differentially modulated in melanoma cells compared to other 
cancers81,240. One of the core functions of melanocytes relies on a unique vesicular trafficking 
processes: the production, trafficking, and secretion of melanosomes, aiding in skin 
pigmentation and protection against damaging solar radiation. Our data demonstrating that 
the melanosome markers Trp1 and Rab27a colocalizes with MT1-MMP-containing EVs and 
subsequent matrix degradation suggests that these cells appear to be utilizing this 
melanocyte-specific pathway to promote invasion and metastasis, and that this process is 
regulated by Coronin 1C. In normal melanocytes, melanosomes mature as they are trafficked 
from the perinuclear region through the cytoplasm to the cell periphery along microtubules 
with the aid of Rab27a and associated motor protein myosin Va241. Once melanosomes reach 
the cell periphery, our understanding of the mechanism of their secretion and transfer 
becomes less clear.  
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Proposed mechanisms for melanosome transport include both vesicle fusion events as 
well as direct PM budding63,241,242. One well supported mechanism involves secretion 
through exocytosis of the melanin core through fusion of the melanosome with the PM72,78,243 
which is consistent with both our staining data and our TEM images of intracellular and 
extracellular vesicles (Fig. 3.6, Sup. Fig. S3.4). Another interesting proposal is that 
melanosomes are transferred to neighboring keratinocytes through the projection of 
filopodia-like structures with bundles of melanosomes presented at the tip for transfer to 
neighboring cells227–229, which shows a striking resemblance to the TEM images acquired of 
our OE cell line (Fig. 3.6D, Sup. Fig S3.4). Given the evidence that cancers can rewire 
lineage-specific signatures to create a growth or metastasis advantage, these trafficking 
pathways may be vital in understanding how Coronin 1C influences MT1-MMP secretion in 
our model, and why the role for Coronin 1C in melanoma seems so different from other 
cancer types. 
Based on these expression data showing Coronin 1C overexpression/upregulation in 
many aggressive cancers21,36,212,213,244, we expected that deletion of Coronin 1C would yield a 
less aggressive tumor with fewer metastases. However, we found that tumors lacking 
Coronin 1C grew faster and were much more metastatic. Although our data are seemingly at 
odds with these over-expression observations, we would point out that correlation does not 
automatically mean causation and hypotheses derived from expression data must be tested 
with functional experiments. Indeed, some experiments using either RNAi depletion or over-
expression in cell lines show that Coronin 1C is a positive regulator of proliferation and 
invasion in breast cancer and lung-squamous cell carcinoma25,39,211. Additionally, Coronin 1C 
was shown to enhance MT1-MMP trafficking to the cell surface in an orthotopic injection 
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model of breast cancer39, which is again seemingly at odds with our results. However, recent 
data using genetic deletion of Coronin 1C in a GEM model of glioblastoma showed no 
change in time of survival with or without Coronin 1C43, further supporting the idea that 
Coronin 1C impacts tumor progression differently between cancer types. We postulate that 
the unique metastatic nature of melanoma and the underlying biology of melanocytes may 
help explain the context-dependent nature of Coronin 1C function in disease progression and 
metastasis. 
Based on our data, the loss of Coronin 1C results in increased secretion of MT1-
MMP-containing extracellular vesicles. Although Coronins are best known to regulate actin 
dynamics in lamellipodia, there is a growing body of literature supporting their function in 
membrane and vesicle trafficking. In HeLa cells, Coronin 1C was identified as a crucial 
regulator of endosomal fission from the endoplasmic33 and has been reported to bind directly 
to GDP-Rab27a to regulate endocytosis31 and insulin exocytosis245 in secretory pancreatic β-
cells. In head and neck squamous cell carcinoma cells, Coronin 1B, a coronin with 
significant homology to Coronin 1C, has been shown to regulate exosome secretion via 
destabilization of the actin network at MVB docking sites through interactions with cortactin 
and Rab27a34. It is possible that Coronin 1C’s influence on the actin cytoskeleton at the PM 
contributes to the increased exosome secretion in our cells either through interactions with 
Rab27a, cortactin, and/or F-actin itself. Coronin 1C has even been shown to bind to MT1-
MMP directly in glioblastoma cells43, but the function of this interaction has not been 





Materials and Methods 
Reagents and materials 
Antibodies for Western blotting, immunofluorescence, and IHC were purchased from Abcam 
(MMP14 [MT1-MMP, [EP1264Y] and CD31 [ab28364]), Takara Bio (GFP [JL8]), Thermo 
Fisher (GAPDH [6C5] and MMP2 [PA5-85197]), and Santa Cruz (HSC70 [B6], CD63 [MX-
49.129.5], TRP1 [TA99], Rab27a [E12A-1], Trp1 [TA99], MT1-MMP [C9, AF647], and 
integrin β1 [A-4]). The Coronin 1C antibody was purified as described previously [51]. 4-
Hydroxytamoxifen, Nexinhib20, and 60 well Nunc MicroWell MiniTrays were purchased 
from Sigma Aldrich. 28 mL Nalgene Oak Ridge High-Speed PPCO Centrifuge Tubes, and 
20 mm Nalgene Sealing Caps for Oak Ridge Centrifuge Tubes were purchased from Thermo 
Fisher. 10KDa Amicon Ultra-15 Centrifugal Filter Units were purchased from EMD 
Millipore. Untreated µ-Slide 8 Well dishes were purchased from Ibidi. 35 mm Dish, No. 1.5 
Coverslip, 20 mm Glass Diameter, Uncoated dishes were purchased from MatTek. A 10 µL 
Microsyringe model 701 and 27GA needle attachments were purchased from Hamilton. 
Genetically engineered mouse models  
The PBT model used was described previously141. Briefly, CreER is expressed under the 
melanocyte-specific promotor Tyrosinase and its activity is regulated spatially and 
temporally by addition of 4-Hydroxytamoxifen (4-HT). Endogenous PTEN is flanked by 
LoxP sites on both alleles, and a WT Braf cDNA is flanked by LoxP sites and followed by 
the V600E mutant form expressed from the endogenous promoter upon deletion of the WT 
cDNA. A Lox/stop/Lox site precedes a TdTomato gene, which upon activation with Cre is 
deleted allowing for TdTomato expression. The PTB-1C model was derived from the PBT 
model with homozygous floxed Coro1C alleles bred in214. Breeding, care, and maintenance 
of each strain were carried out in accordance to UNC’s Division of Laboratory Animal 
Medicine- and Institutional Animal Care and Use Committee-approved protocols and 
standards. Genotyping for correct PTEN, BRAF, TdTomato, Cre, and Coro1C is completed 
from DNA isolated from toe clips of pups before use in experimentation.   
Tumor induction and measurement in GEM models  
Tumors were induced in PBT and PBT-1C mice by local application of 4-HT to the left ear 
of 7-8-week-old PBT and PBT-1C mice of both sexes as described previously141. Briefly, 1 
µL of 20 mM 4-HT solution in DMSO, 100% ethanol, and orange-6 dye was applied under 
anesthesia for precisely nine minutes before the area was thoroughly washed with 70% 
ethanol. Tumor growth was quantified by measuring the thickness of the ear where the tumor 
was induced every seven days by caliper while the mice were anesthetized with 1.5% 
isoflurane. 
Cell lines 
All cells were cultured in DMEM with 10% FBS at 37⁰C and 5% CO2. A Coronin 1C-null 
cell line (referred to all Null throughout the paper) was isolated from a brain metastasis from 
a male PBT-1C mouse induced with 4-HT by surgical resection of the tumor, dissociation in 
0.25% trypsin/EDTA, and selected by FACS for TdTomato expression. Western blot analysis 
confirmed that the cell line was null for Coronin 1C as well as Pten. Mouse Coronin 1C fused 
to GFP on its C-terminus in the lentiviral vector pLL5.0246 was packaged into viral particles 
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using HEK293FT cells. Null cells were incubated with this virus for 36 hours. Infected cells 
were selected by FACS sorting for GFP expression and expanded. Single GFP-positive cells 
were sorted into a 96-well plate for clonal expansion by the UNC Flow Cytometry Core 
Facility. Clonal populations were screened for Coronin 1C expression levels using Western 
blotting. One clonal population was identified as having endogenous Coronin 1C expression 
compared to line PBT2460 isolated from the PBT model167 and we designated this line 
Rescue. Another clonal population showed ~2x higher Coronin 1C expression and was called 
OE. TdTomato-negative cell lines were generated by targeting TdTomato using the Zhang 
Lab lentiviral CRISPR toolbox protocol and lentiCRISPR v2 construct247,248. Cells infected 
with the construct were selected using 10 µM puromycin, and the cells were then sorted for 
lack of TdTomato expression using FACS.  
Macro-metastasis identification 
Mice were sacrificed when the primary tumor began to ulcerate via CO2 euthanasia and 
cervical dislocation according to UNC’s Institutional Animal Care and Use Committee 
guidelines. Organs were harvested, placed in sterile PBS and imaged with an Olympus 
MVX10 macroscope system. TdTomato+ macro-metastases were identified using 
fluorescence and appropriate filter sets in conjunction with Metamorph software.   
Micro-metastasis identification 
Organs that had been scanned for macro-metastases were prepped for micro-metastasis 
identification protocol adapted from a previous method249, then transferred to 6 cm dishes 
and minced with a razor blade in 0.5 mL of sterile PBS. The dish was then rinsed with 1 mL 
of PBS and all the contents transferred to a 15 mL conical tube. These were spun at 1000 rpm 
for three minutes and the supernatant was removed. The pellets were then resuspended in 
0.25 – 1 mL of 300 U/mL collagenase and 100 U/mL hyaluronidase in DMEM, incubated for 
1hr at 37⁰C with vortex mixing at 30min. The mixtures were again pelleted and the 
supernatant was removed, followed by wash with 1 mL PBS. At this point, brain tissue was 
set aside because it did not require further dissociation. The remaining organ mixtures were 
resuspended in 0.25% trypsin/EDTA and incubated for 21 minutes at 37⁰C with a vortex mix 
every 7 minutes, before being spun down and rinsed with 1 mL PBS. All dissociated organs 
were resuspended in 0.5 mL ice cold PBS and fixed with 4.5 mL ice cold 4% PFA for 15 
minutes. Cells were then spun down and rinsed with 1 mL of PBS for 5 minutes and stored at 
4⁰C for no longer than 48 hours before analysis. Cells were prepped for sorting according to 
protocol outlined previously250 and profiled with a Bio-Rad S3 Cell Sorter. TdTomato+ 
threshold was set by the profile of TdTomato-expressing Coronin 1C-defincient Null cell line 
as outlined below. Uninduced PBT and PBT-1C mice (not treated with 4-HT) were used as a 
negative control by profiling each organ for endogenous TdTomato expression. For each 
organ type, the mean number of cells that fell inside of the TdTomato+ threshold plus the 
95% confidence intervals were calculated so that each organ had its own unique threshold 
based on endogenous autofluorescence of the tissue.  Any induced mouse organ TdTomato 
profile that fell above the control 95% confidence interval was considered a positive hit for a 
micro-metastasis.  
Immunohistochemistry 
Tumors were harvested from the base of the ear, fixed in 4% PFA for 24 hours at 4⁰C and 
preserved in 30% sucrose at 4⁰C. Fixed tumors were washed for 24 hours in PBS and paraffin 
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embedded for sectioning. Sections underwent heat-induced epitope retrieval and were 
chromogen stained for CD31 with Vector Red and counterstained with hematoxylin. 
Sectioning and staining were preformed by the Histology Research Core Facility in the 
Department of Cell Biology and Physiology at the University of North Carolina at Chapel 
Hill.  
Depletion of MT1-MMP by shRNA  
shRNAs against mouse MT1-MMP were acquired from the UNC-CH Lenti-shRNA Core 
Facility in pLKO.1 vectors. Lentiviruses expressing these shRNAs were generated using 
standard packaging methods in HEK293FT cells as described previously251 and were used to 
infect Null, Rescue, and OE cells for 36 hours. Infected cells were selected by 10 µM 
puromycin and knockdown was assessed by western blotting. All experiments were 
completed with 3 passages following puromycin selection. The targeting sequences for MT1-
MMP were: (sh1) CCATCAATACTGCCTACGAAA; (sh2) 
GCAGTGATGAAGTCTTCACAT.   
Zymography  
80% confluent 6 cm dishes were rinsed with PBS and covered with 4 mL of serum-free 
DMEM. After 24 hours, 3.5 mL of this conditioned media was removed and concentrated to 
250 µL using Amicon Ultra-15 Centrifugal Filters. Conditioned media volumes were 
normalized according to cell count from the dishes of origin and incubated with 2x SDS 
loading buffer without 2-mercaptoethanol for 20 minutes at 37⁰C before being loaded into a 
10% SDS gel containing 0.1% porcine gelatin. Gels were run at 200 V packed on ice until 
the 37kd marker ran off of the gel, then washed four times for 30 minutes each at room 
temperature with wash buffer (25 mM Tris pH 7.6, 5 mM CaCl2, 3 mM NaN3, 0.25 nM 
ZnCl2, and 1.25% Triton-X100 in water). The gel was then washed with ddH2O for 30 
minutes before incubation for 36 hours at 37⁰C in incubation buffer composed of 25 mM Tris 
pH 7.6, 5 mM CaCl2, 3 mM NaN3 and 0.375 M NaCl in water. The gel was then quickly 
rinsed in distilled water before staining with 0.1% Coomassie Blue solution for 1 hour. After 
destaining for about 30 minutes, the gel was imaged using a Bio-Rad ChemiDoc MP Imaging 
System. Band intensity was quantified using Image Lab 6.0.1 software and graphed in 
GraphPad Prism. 
Western blotting and immunostaining  
Western blotting was performed as described previously252. Conditioned media loading was 
controlled by normalizing the volume to the number of cells counted from the dish which the 
media was removed. Band intensity was quantified using Image Lab 6.0.1 software and 
graphed in GraphPad Prism. Immunostaining of cells on either 2D gelatin matrix or 
fibronectin-coated glass was done following a previously published protocol253.   
Cell spheroid generation: hanging droplet method 
Cells in culture were suspended at 100,000 cells/mL. 24 µL of suspension was added to each 
well of a Nunc MicroWell MiniTray and inverted. Dishes were placed inside of a 15 cm 
culture dish humidified with 8 mL of PBS inside an open 6 cm dish. Spheroids were left to 




Nude mouse spheroid injection 
Cell spheroids plus 1-1.5 µL of sterile PBS were injected into the left ear of nude mice 
anesthetized with 1.5% isoflurane using a Hamilton Microliter Syringe with a 27GA needle 
142. Primary tumor growth was monitored weekly and imaged on an Olympus MVX10 
macroscope system. Mice were sacrificed via CO2 euthanasia and cervical dislocation 
according to UNC’s Institutional Animal Care and Use Committee guidelines when the 
primary tumor began to ulcerate and were processed by the macro- and micro-metastasis 
identification protocol.  
Microscopy  
Fixed-cell and live-cell images of 3D spheroid invasion, 2D matrix degradation, and cells 
plated on glass coverslips were captured with a Zeiss LSM800 microscope with a 10x, 40x, 
or 63x objective using both confocal and airyscan settings. Movies and images were 
processed on both Zen Blue and Fiji software. IHC slides were imaged using an Olympus 
BX51 microscope with a 40x objective using Metamorph software. TEM was performed by 
the University of North Carolina’s Microscopy Services Laboratory.  
2D collagen matrix degradation  
Acid-washed coverslips were coated with a 2D FITC-conjugated collagen matrix previously 
described250. Equal numbers of each cell type were plated onto the gel-coated coverslips in 
12 well dishes for 24 hours before fixation and staining. Degradation spots were counted 
manually. Calculations of matrix area devoid of cells was determined by using a custom 
MATLAB script to identify cell area and subtracting that value from the total area of the 
image. Briefly, the code uses the image processing toolbox to threshold the cell boundary 
from fluorescent cell images and calculates the area within that boundary in order to 
determine the area of matrix in uninhabited by a cell body. The code used in this study and a 
sample data set is openly available on GitHub along with auxiliary scripts accessible for 
download at https://github.com/maxhocken/SuperfineBear     
3D matrix invasion 
Gel matrix composed of 1 mg/mL rat tail collagen, 1X DPBS, and 3.3 mM NaOH dissolved 
in sterile water. 100 µL of gel mix was used to coat the bottom of each glass-bottomed 
chamber slide well and solidified at 37⁰C for 1 hour. One spheroid was suspended in 100 µL 
of gel mix and pipetted on top of the primary gel layer and solidified for 1 hour at 37 ⁰C and 
then overlaid with 100 µL of DMEM to avoid drying out. Chamber slides were then imaged 
every 10-20 minutes for 16 hours with a Zeiss LSM800 confocal microscope in 51 Z planes 
across 200 µm. Maximum intensity projection movies were generated with Zen Blue 
software and invading cells were tracked using the manual tracking tool on Fiji. Velocities 
were calculated using the chemotaxis plugin on Fiji. Temperature, humidity, and CO2 levels 
were maintained by a Tokai Hit chamber regulator.   
Surface MT1-MMP quantification 
Cells were plated on FN-coated glass coverslips and fixed with 4% PFA. After three 10-
minute washes with PBS, cells were blocked for 30 minutes in 10% BSA and 10% NGS in 
PBS. Without permeabilizing the cells, surface MT1-MMP was labeled via incubation with 
AlexaFluor647-conjugated MT1-MMP primary antibody for 1 hour in 1% BSA in PBS. The 
cells were rinsed three times for 10 minutes with PBS, then mounted onto slides for imaging 
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using a Hamamatsu Orca-flash 4.0LT camera on a Zeiss800 microscope and 40x objective. 
MT1-MMP surface expression was quantified by calculating the integrated pixel density of 
individual cells across 3 biological replicates, as previously described12. Briefly, images were 
imported into Fiji and the TdTomato signal from the cells was used to carefully trace an 
outline for each cell. Integrated pixel density of the AlexaFluor647 signal was measured and 
calculated for each individual cell using Fiji’s measurement tool.  
Ultracentrifugation 
Three 10-cm dishes of 80% confluent cells were rinsed with PBS before incubation with 10 
mL each of serum-free DMEM for 48 hours. CM was collected and cell debris was spun out 
at 5,000 g for 15 minutes and discarded. 25 mL of supernatant was transferred to 
ultracentrifuge tubes and spun at 10,000 g for 30 minutes. Supernatant was transferred to 
clean ultracentrifuge tubes and spun at 100,000 g for 2 hours. The pellets from the 10,000 g 
and 100,000 g spins were resuspended in 400 µL of PBS containing protease inhibitor 
cocktail and run out in western blots for protein detection.  
2D migration assay 
Equal numbers of cells were either plated on 2D collagen matrix or glass-bottomed Mat-Tek 
dishes coated with 10 µg/mL fibronectin for 1 hour and rinsed with PBS. Cells were given 4 
hours to adhere before imaging every 10 minutes with a VivaView microscope for 16 hours. 
Movies were generated with Metamorph software and individual cells were tracked in Fiji 





Supplemental Figure S3.1: IHC of primary tumors reveals greater CD31 intensity 
around blood vessels in PBT-1C tumors. 
A) Representative images of chromogenic IHC staining of CD31 with ImmPACT Vector 
Red and hematoxylin counterstain. Primary tumors were harvested 7 and 10 weeks after 
induction with 4-hydroxytamoxifen. Blood vessels with a visible lumen surrounded with 
CD31 signal are highlighted with black arrows. Scale bars = 50 µm. B) Representative 
zoomed in images of slides imaged in (A) showing the intensity of CD31 signal surrounding 
blood vessel lumen in PBT and PBT-1C primary tumors 10 weeks after induction with 4-
hydroxytamoxifen. Scale bar = 25 µm. C) Mean +/- SEM of blood vessel diameter at widest 
section measured from images taken from IHC described in (A). N of one tumor per 
condition, >12 vessels for each condition. Unpaired T tests revealed no significant 





Supplemental Figure S3.2. Coronin 1C rescue shows predicted localization and 
increases proliferation rate. 
A) Airyscan images of fixed Null, Rescue, and OE cells with Coronin 1C-GFP expression, 
stained for F-actin with phalloidin-647. 63x objective, scale bar = 10 µm. B) Growth curve of 
Null, Rescue, and OE cells with 10,000 cells plated on day 0. Time points taken every 24 






Supplemental Figure S3.3. MMPs and vesicle markers are identifiable by IF and 
western blotting of resuspended pellets following ultracentrifugation of conditioned 
media in Null cells. 
A-B) Immunofluorescent images of TdTomato CRISPR knockout Null cells plated for 24 
hours on 2D FITC-gelatin stained for F-actin with phalloidin-568 and immunolabeled with 
HSC70 (A) and β1integrin. Full-sized image scale bars = 5 µm. Zoom image scale bars = 1 
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µm. C-F) Western blots of EVs pelleted from conditioned media at 10,000 x g and 100,000 x 
g probed for HSC70 (C), β1integrin (D), Rab27a (E), and MMP2 (F). G) Immunofluorescent 
images of Null cells plated for 24 hours on 2D FITC-gelatin immunolabeled with MMP2. 
Full-sized image scale bars = 5 µm. Zoom image scale bars = 1 µm. H) Zymography gel of 
conditioned media from Null, Rescue and OE cells side by side with western blots of EVs 
pelleted from conditioned media at 10,000 x g and 100,000 x g probed for MT1-MMP and 
MMP2 overlaid with white light images so that the transferred protein ladder is visible along 
with the antibody detection. 
 
 
Supplemental Figure S3.4. Coronin 1C re-expression results in increased vesicle 
buildup, and abnormal vesicle production and presentation. 
A) Transmission electron microscopy of Null cells shows release of multicompartmental EVs 
and fewer vesicles built up in the cytoplasm along the PM. Scale bars left to right: 500 nm, 
500 nm, 500 nm, 200 nm. B) Transmission electron microcopy of Rescue cells showing an 
abundance of various abnormal vesicular bodies built up in the cytoplasm. Scale bars left to 
right: 500 nm, 250 nm, 500 nm, 250 nm. C) Transmission electron microscopy of OE cells 
displaying an abundance of various abnormal vesicular bodies built up in the cytoplasm and 
presentation of vesicles at the end of filopodia-like projections. Scale bars left to right: 500 





Supplemental Figure S3.5. Inhibition of Rab27a with Nexinhib20 reduces extracellular 
degradation in Null cells. 
Null, Rescue and OE cells were treated with either 1 µM Nexinhib20 or equal volume 
DMSO for 1 hour, then plated on FITC-conjugated 2D gelatin matrices for 24 hours in media 
containing either drug or DMSO. Cells were fixed and stained with MT1-MMP and Rab27a. 
Black spots in the gel matrix are indicative of degradation of the gelatin layer. A) Percent of 
cells that contain degraded spots of the matrix beneath the cell body. B) Number of degraded 
spots per cell showing degradation. C) Number of degraded spots per area of 2D matrix 
uninhabited by a cell body. N cells A-C >30 from 3 biological replicates. D) Example image 
of Null cell treated with 1 µM Nexinhib20. MT1-MMP and Rab27a localize with spots of 
degradation. Scale bar in merge = 2.5 µm and scale bar in zoom merge = 1 µm. * = P <.05, 









Supplemental Figure S3.6. Treatment with MT1-MMP shRNAs results in knockdown 
stable for 3 passages. 
A) Western blot of whole cell lysates of Null, Rescue, and OE cells 2 passages after infection 
with MT1-MMP-targeting shRNA lentivirus and selection via puromycin treatment. Blots 
were probed with MT1-MMP and GAPDH for loading control, run with the same sample and 
volume but on a different gel, and cut for ease of probing with antibodies at low volume. B) 
Western blot of whole cell lysates from Null cells infected with MT1-MMP-targeting shRNA 
lentivirus 1-4 passages after puromycin treatment, compared with Null cells with mock 
infection. Blots were probed with MT1-MMP and GAPDH for loading control, run with the 
same sample and volume but on a different gel, and cut for ease of probing with antibodies at 




Supplemental Figure S3.7. Western blots of whole cell lysates to supplement main 
figures. 
A) Western blot of the Null, Rescue, and OE cell lines compared to PBT2460, a cell line 
isolated from a Pten/Braf melanoma tumor with endogenous Coronin 1C. Blots were probed 
with MT1-MMP and GAPDH for loading control, run with the same sample and volume but 
on a different gel, and cut for ease of probing with antibodies at low volume. B) Low 
exposure image of a western blot of Null, Rescue, and OE WCLs probed with MT1-MMP 
and GAPDH loading control. Blots were probed with MT1-MMP and GAPDH for loading 
control, run with the same sample and volume but on a different gel, and cut for ease of 





 CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
Summary and Impact 
Loss of Coronin 1C yields more aggressive melanoma 
 The loss of Coronin 1C in this melanoma model resulted in a significant increase in 
the rate of primary tumor growth and a detrimental surge in metastasis. The increase in tumor 
cell invasion was confirmed in vivo through comparison of metastases after orthotopic 
injection of either Coronin 1C-null tumor cell (Null) spheroids or those re-expressing 
endogenous-level Coronin 1C (Rescue) or overexpressed levels the protein (OE). The rate of 
metastasis to the brain and liver was inversely correlated with Coronin 1C expression, and 
the invasive capacity of these Null cells were quantified in vitro through 3D collagen 
spheroid invasion and 2D gelatin degradation144. 
 These results were surprising given the number of studies suggesting that Coronin 1C 
is upregulated in melanoma and other cancer types21,35–39. In fact, this is the first published 
example of Coronin 1C acting as a tumor suppressor in any form of cancer to our knowledge. 
While it is true than Coronin 1C expression is associated with poor prognosis in many 
cancers when analyzing TCGA survival curves, it is worth recognizing that these types of 
correlations lack significant prognostic power and oftentimes the function of an upregulated 
protein either has no impact on tumor progression or actually serves as a tumor suppressor254. 
Further investigation of mutation signatures of Coronin 1C in human melanoma on the 
cancer genomics database website cBioPortal255 reveals a wide variety of mutations across 
the entire gene, more indicative of a pattern of loss of function mutations as opposed to gain 
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of function or constitutive activation. If this is the case, the resulting Coronin 1C protein (if it 
is even able to be translated) may be non-functional even though there is frequently an 
increase in mRNA copy number. This is just one example of why it is paramount to develop 
well controlled models of disease that closely recapitulate the native tumor environment to 
generate reproducible and reputable data.  
 One might still wonder why Coronin 1C expression levels are elevated in melanoma 
if it is not contributing to the overall survival or invasiveness of the cell. The answer to that 
question may lie in the complexity of Coronin 1C’s transcriptional regulation that is not 
present in other type 1 coronins, described in chapter 1. Erk signaling is a known mechanism 
for transcriptional activation of Coronin 1C21 and is stimulated by the upstream regulator 
Braf which is the most common driver mutation in human melanoma. Constitutive activation 
of Braf occurs in about 50% of melanoma cases, leading to a signaling cascade that activates 
Erk256. Erk signaling is functionally linked with tumor progression and is upregulated in 
many other cancer types leading to a large variety of genome-wide transcriptional changes in 
addition to Coronin 1C that aid in survival, invasion, and angiogenesis257,258. This activation 
of Erk through Braf for the purpose of regulating the transcription of these other pro-
tumorigenic genes may help to explain why Coronin 1C copy number increases are 
correlated with poor prognosis. 
Coronin 1C inhibits invasion through regulation of MT1-MMP 
  Coronin 1C-null cells isolated from a tumor in the PBT-1C GEM model are highly 
efficient in degrading gelatin and collagen in our in vitro system, and re-expression of 
Coronin 1C-GFP in these cells inhibits this degradation in an expression-dependent manner. 
We discovered that the high levels of degradation and subsequent melanoma cell invasion 
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observed is dependent upon the secretion of MT1-MMP on EVs, and that re-expression of 
Coronin 1C inhibits this process144. Coronin 1C null cells are more invasive in 3D but 
migrate slower on 2D glass (Figure 3.3), which actually aligns with conclusions drawn from 
Coronin 1C loss in other cancer types discussed previously. Since MMPs typically do not 
impact 2D migration90, this result supports our conclusion that MT1-MMP secretion is 
crucial for modification of the surrounding ECM, allowing for 3D invasion and in vivo 
metastases seen in our animal models, and begs the question as to whether Coronin 1C has a 
similar impact on 3D migration in other cancer types that have not yet been tested in a 
physiologically-relevant manner. 
 As described in chapter 1, the important role for MT1-MMP in cancer cell invasion 
and metastasis is well appreciated, although the connection between MT1-MMP and Coronin 
1C is just beginning to emerge. The limited literature on the topic suggests that Coronin 1C 
acts as an oncogene as opposed to a tumor suppressor in breast cancer and glioblastoma, 
increasing the activity of MT1-MMP to promote invasion39,43. While initially this appears as 
another reason to be surprised by our conclusions, the presence of the late-stage 
melanosome-marker Trp1 on secreted EVs provides an important clue as to why Coronin 1C 
may be impacting melanoma tumor progression differently than other cancer types.  
 There is one paper in the literature that functionally links melanosome-related EVs to 
melanoma progression. These EVs were recognized by the Human Melanoma Black 
antibody HMB-45 that recognizes  the pre-melanosome protein (Pmel) antigen259 and also 
contained miR-201 that encourages the differentiation of fibroblasts into cancer-associated 
fibroblasts (CAFs) which help prime tissues for a pre-metastatic niche. Other groups have 
also found that Pmel is present during large scale screenings of melanoma EV components, 
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but our results were the first to identify a late stage melanosome marker in melanoma-
associated EVs to our knowledge. 
Future Directions 
Identify mechanism of MT1-MMP regulation by Coronin 1C 
 The most pressing next step will be to identify how Coronin 1C is influencing the 
secretion of MT1-MMP- and Trp1-containing EVs. Given the data in Figures 3.4 and 3.7 
demonstrating only small changes in classical invadopodia formation upon modulation of 
protein expression, Coronin 1C is likely influencing MT1-MMP recycling and/or secretion 
elsewhere in the cell. Classical MT1-MMP recycling involves a variety of Rab proteins 
including Rab5, Rab7110,204, Rab8208, and Rab27a209 that traffic internalized vesicles 
throughout the endolysosomal pathway. Based on what has previously been discovered about 
Coronin 1C’s role in trafficking, there are numerous possibilities for sites of regulation along 
this pathway. 
Visualizing the process of MT1-MMP recycling will require elegant fluorescent 
labeling of protein or cell structures followed by microscopy. Ideally, endogenous MT1-
MMP would be labeled on the surface of live cells and then tracked through different 
structures as it is internalized and recycled in order to identify its path through the cell. We 
have begun the process of using a fluorescence-conjugated MT1-MMP antibody to label live 
cells and fix at various time points to visualize their localization pattern after internalization 
from the PM (Figure 4.1). Pairing this technique with Coronin 1C imaging and staining for 
different cell structures and proteins involved in various steps of the endolysosomal pathway 
will help to identify the process by which these MT1-MMP-containing EVs are being 




Figure 4.1. MT1-MMP internalization assay  
Airyscan images of Null, Rescue, and OE cells after live-cell immunostaining of surface 
level MT1-MMP with an AlexaFluor647-conjugated primary antibody at 4⁰C either fixed 
immediately after wash with 37⁰ DMEM (A) or incubated for 30 minutes to allow for 
internalization. Scale bar = 25µm. 
 
 Internalization of MT1-MMP is the first step of protein recycling that is necessary for 
relocation of MT1-MMP to the invasive lead of the cell203,260. In pancreatic β cells, Coronin 
1C is necessary for efficient endocytosis of the PM in conjunction with its binding partner 
Rab27a210. Interestingly, Coronin 1C specifically binds to the GDP-bound Rab27a and while 
this interaction seems to be necessary for endocytosis, exactly how these proteins influence 
membrane internalization is not well understood. In order to identify if Coronin 1C 
expression influences the rate of internalization of the PM in this system, I would use a live-
cell fluorescent PM marker such as CellBriteTM to label the membrane and then fix the cells 
at multiple timepoints after labeling to measure the differences in the number of cytosolic 
fluorescent vesicles indicative of endocytic events. If possible, I would pair this with live cell 
imaging of Coronin 1C-GFP to see where it is localizing during endocytic events.  Figure 3.5 
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demonstrates that the intensity of surface-level MT1-MMP correlates positively with Coronin 
1C expression while whole cell expression levels do not change. This might suggest that 
Coronin 1C actually inhibits endocytosis, but Coronin 1C may instead work further down the 
endolysosomal pathway to help promote invagination of the vesicle membrane and shunt 
MT1-MMP-containing vesicles toward the PM for secretion as opposed to recycling to the 
surface of the PM.  
 In COS7 cells Coronin 1C localization to endosomal buds is required for efficient 
fission from Rab7-coated recycling endosomes at the endoplasmic reticulum33. Coronin 1C 
then remains on these newly formed vesicles along with WASH, Arp2/3, and associated 
branched actin, though its function after fission is not well understood. If this model holds 
true in our system, and if these budded vesicles are destined for the traditional fates of either 
lysosomal degradation or relocation to the PM for re-expression, then the loss of Coronin 1C 
could prevent these budding and PM trafficking events from occurring. Instead, the recycling 
MT1-MMP could be shunted toward a different pathway that encourages MVB formation 
and subsequent EV secretion.  
Since Coronin 1C is also thought to influence branched actin dynamics, its presence 
on the newly formed vesicles along with WASH and Arp2/3 suggest that it may be impacting 
the actin network surrounding the vesicle. WASH-dependent actin assembly has been 
documented on MT1-MMP-containing vesicles103 and branched actin on the surface of 
endosomes has been proven to be important for stabilization tubules for transport261 as well 
as for biogenesis of multivesicular bodies262, and may even determine the target destination 
of the endosome by regulating Rab protein dynamics103,261,263. Identifying the Rab protein 
coat of MT1-MMP-containing vesicles following internalization within our three-cell model 
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through immunofluorescent microscopy and eventual live-cell imaging with fluorescent 
fusion proteins will help be an important step toward understanding Coronin 1C’s role in 
MT1-MMP secretion events.  
Branched actin also plays a dynamic role during MVB fusion to the PM for exosome 
release. A stable branched actin network is required for docking of MVBs at the PM, and 
destabilization of this network by proteins such as Cortactin can prevent MVB fusion. 
Coronin 1B has been implicated in perturbing this process in head and neck squamous cell 
carcinoma cells by antagonizing Cortactin-mediated stabilization of docking sites34, and it is 
possible that Coronin 1C could have a similar impact. In this system Coronin 1B was also 
perturbed the presence of Rab27a, though direct binding of these two proteins has not been 
demonstrated. In support of this hypothesis, the TEM images of our Null, Rescue, and OE 
cells in Figures 3.6 and S3.4 demonstrate a buildup of abnormal MVBs and vesicular 
structures around the PM, possibly indicative of unstable docking site for secretion.  
Coronin 1C has not yet been implicated in exosome release, but it has a demonstrated 
ability to bind and be sequestered by GDP-bound Rab27a31. In Figure S3.5 we show that 
Rab27a localizes to sites of extracellular degradation, indicative of release on MT1-MMP-
containing EVs. Additionally, treatment of Null cells with the Rab27a inhibitor Nexinhib20 
drastically decreased extracellular degradation of gelatin. Rab27a in its GTP-bound state is 
required for the successful transport of late endosomes and MVBs to the periphery for fusion 
with the plasma membrane and subsequent cargo release into the extracellular space264–267. It 
is possible that binding of Rab27a-GDP by Coronin 1C inhibits the pool that is available for 
nucleotide exchange, thus reducing the amount of Rab27a-GTP available to facilitate MVB 
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transport and docking. If this is the case, loss of Coronin 1C would lead to a bigger pool of 
Rab27a-GTP potentially heightening the rate of EV secretion.  
Rab27a is also well known for its role in the transport of mature melanosomes to the 
cell periphery by acting as a bridge between the melanosome and Myosin Va, along with 
Mlph268. The identification of both Rab27a and Trp1 (a late melanosome marker) on the 
MT1-MMP-containing EVs strongly suggests an irregular mash-up of multiple trafficking 
pathways that results in regulation of MT1-MMP-containing vesicles by members of the 
melanosome biogenesis and trafficking machinery. Based upon the known interaction of 
Coronin 1C with Rab27a, the importance of this protein in trafficking, and our functional 
data demonstrating that Rab27a is involved in MT1-MMP secretion in our system, there is a 
strong possibility that this is where Coronin 1C acting.  
To confirm that Rab27a and Coronin 1C are interacting in our model, either a BioID 
assay or an immunoprecipitation (IP) assay, using Coronin 1C-GFP as bait and blotting for 
Rab27a, would be a good first step. Eventually generating lentiviral constructs for stable 
expression of fluorescently labeled Rab27a, MT1-MMP, and Trp1 to use for live cell 
imaging would be an ideal way to visualize how and where these proteins interact with one 
another inside and outside of the cell. 
Non-ECM roles for MT1-MMP 
The tumorigenic activity of MT1-MMP is most often associated with either direct 
proteolysis of ECM components or indirect proteolysis via activation of MMP2 through 
cleavage of its pro-peptide104. However, there is a growing body of literature suggesting that 
MT1-MMP acts beyond this catalytic role to promote cancer progression by regulating 
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signaling pathways contributing to angiogenesis, proliferation, cell migration, and increased 
metabolism.  
Multiple studies have demonstrated that MT1-MMP increases VEGF secretion in 
cancer cells, raising the potential for angiogenesis which is crucial for feeding a growing 
primary tumor, creating sites of intravasation, and establishing a metastatic niche118,199,269,270. 
The cytosolic tail of MT1-MMP was shown to form a complex with VEGFR-2 and Src in 
breast cancer cells leading to a signaling cascade that resulted in mTOR-mediated 
transcription of VEGF-A118. A simple western blot from conditioned media on our cells may 
be enough to identify changes in VEGF secretion upon Coronin 1C rescue. Examining the 
vasculature of the primary tumors of the PBT and PBT-1C GEM models would also help 
identify differences in vessel number, structure, and subsequent blood supply, which could 
be done through venous injection with fluorescently labeled Dextran and intravital imaging. 
If changes in MT1-MMP activity in Coronin 1C-null tumors are contributing to the 
upregulation of VEGF and increased angiogenesis, this may help to explain the heightened 
rate of primary tumor growth and further promote metastasis events.  
Elevated Src activation and downstream signaling is also associated with an increased 
mitotic rate in cancer cells271–273. In addition, MT1-MMP has also been implicated in the 
activation of the embryonic stem cell factor Notch1, driving melanoma cell proliferation224. 
Blotting for Notch1 and phosphorylated (activated) Src in WCLs of our three cell lines could 
provide some insight as to whether these signaling pathways are modulated by the change in 
MT1-MMP activity mediated by Coronin 1C. These non-catalytic functions may help to 
explain the heightened rate in primary tumor growth and further promote the invasion and 
metastasis phenotypes observed.  
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In addition to the well-known ECM-degrading role for MT1-MMP, it also modulates 
the pericellular environment through cleavage of non-ECM proteins. Pro-MMPs are cleave 
by MT1-MMP for activation and cleavage of CD44, the integrin αV chain, low density 
lipoprotein receptorrelated protein, interleukin 8, and pro-tumor necrosis factor274. It is 
possible that in addition to the clear degradative capacity of MT1-MMP in these cells, MT1-
MMP may also be influencing cell behavior through a variety of other known catalytic 
targets. Further investigation will be necessary for a complete understanding of the behavior 
of MT1-MMP in melanoma.   
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